WO1996009062A1 - Polypeptide agonists and antagonists of human interleukin-8 - Google Patents
Polypeptide agonists and antagonists of human interleukin-8 Download PDFInfo
- Publication number
- WO1996009062A1 WO1996009062A1 PCT/US1995/012099 US9512099W WO9609062A1 WO 1996009062 A1 WO1996009062 A1 WO 1996009062A1 US 9512099 W US9512099 W US 9512099W WO 9609062 A1 WO9609062 A1 WO 9609062A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cys
- lys
- leu
- xaa
- sequence
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 91
- 239000000556 agonist Substances 0.000 title abstract description 29
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 26
- 239000005557 antagonist Substances 0.000 title abstract description 21
- 229920001184 polypeptide Polymers 0.000 title abstract description 14
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 title description 16
- 102000052624 human CXCL8 Human genes 0.000 title description 3
- 108050006947 CXC Chemokine Proteins 0.000 claims abstract description 49
- 102000019388 CXC chemokine Human genes 0.000 claims abstract description 49
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 16
- 201000004681 Psoriasis Diseases 0.000 claims abstract description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 4
- 208000032839 leukemia Diseases 0.000 claims abstract description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims abstract 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims abstract 2
- 150000001413 amino acids Chemical class 0.000 claims description 65
- 235000001014 amino acid Nutrition 0.000 claims description 64
- 238000000034 method Methods 0.000 claims description 23
- 235000018417 cysteine Nutrition 0.000 claims description 13
- -1 antifungals Substances 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 210000004899 c-terminal region Anatomy 0.000 claims description 9
- 150000001945 cysteines Chemical class 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- SCEJQXRUWDSIBB-UHFFFAOYSA-N 2,2-diaminooctanedioic acid Chemical compound OC(=O)C(N)(N)CCCCCC(O)=O SCEJQXRUWDSIBB-UHFFFAOYSA-N 0.000 claims description 6
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 230000001270 agonistic effect Effects 0.000 claims description 5
- 230000003042 antagnostic effect Effects 0.000 claims description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 5
- 239000004615 ingredient Substances 0.000 claims description 5
- 206010017533 Fungal infection Diseases 0.000 claims description 4
- 229940124277 aminobutyric acid Drugs 0.000 claims description 4
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 4
- 230000001472 cytotoxic effect Effects 0.000 claims description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 3
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 208000031888 Mycoses Diseases 0.000 claims description 2
- 208000030852 Parasitic disease Diseases 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 208000037976 chronic inflammation Diseases 0.000 claims description 2
- 231100000433 cytotoxic Toxicity 0.000 claims description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- 230000001575 pathological effect Effects 0.000 claims 4
- QWCKQJZIFLGMSD-UHFFFAOYSA-N 2-Aminobutanoic acid Natural products CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 claims 2
- QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- OSASDIVHOSJVII-WDSKDSINSA-N Arg-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCNC(N)=N OSASDIVHOSJVII-WDSKDSINSA-N 0.000 claims 1
- 108010036941 Cyclosporins Proteins 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- WTUJZHKANPDPIN-CIUDSAMLSA-N Ser-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N WTUJZHKANPDPIN-CIUDSAMLSA-N 0.000 claims 1
- 208000038016 acute inflammation Diseases 0.000 claims 1
- 230000006022 acute inflammation Effects 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000002456 anti-arthritic effect Effects 0.000 claims 1
- 230000002141 anti-parasite Effects 0.000 claims 1
- 229940124346 antiarthritic agent Drugs 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000003096 antiparasitic agent Substances 0.000 claims 1
- 229940125687 antiparasitic agent Drugs 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 229940121357 antivirals Drugs 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- 208000037920 primary disease Diseases 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 abstract description 149
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 abstract description 149
- 102000004890 Interleukin-8 Human genes 0.000 abstract description 145
- 229940096397 interleukin-8 Drugs 0.000 abstract description 141
- 230000000694 effects Effects 0.000 abstract description 38
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 4
- 230000001404 mediated effect Effects 0.000 abstract description 4
- 208000035473 Communicable disease Diseases 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 241000894006 Bacteria Species 0.000 abstract description 2
- 241000233866 Fungi Species 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 230000000973 chemotherapeutic effect Effects 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 244000005700 microbiome Species 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 229940024606 amino acid Drugs 0.000 description 51
- 210000000440 neutrophil Anatomy 0.000 description 43
- 210000004027 cell Anatomy 0.000 description 33
- 230000027455 binding Effects 0.000 description 31
- 102000005962 receptors Human genes 0.000 description 28
- 108020003175 receptors Proteins 0.000 description 28
- 241001465754 Metazoa Species 0.000 description 20
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 19
- 102000019034 Chemokines Human genes 0.000 description 18
- 108010012236 Chemokines Proteins 0.000 description 18
- 210000001616 monocyte Anatomy 0.000 description 18
- 102000016950 Chemokine CXCL1 Human genes 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 17
- 102100030304 Platelet factor 4 Human genes 0.000 description 17
- 230000004071 biological effect Effects 0.000 description 17
- 238000002347 injection Methods 0.000 description 17
- 239000007924 injection Substances 0.000 description 17
- 125000003275 alpha amino acid group Chemical group 0.000 description 16
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 16
- 108090000778 Platelet factor 4 Proteins 0.000 description 15
- 239000002975 chemoattractant Substances 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 14
- 238000001727 in vivo Methods 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 14
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 description 13
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 description 13
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 13
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 13
- 239000011575 calcium Substances 0.000 description 13
- 102000010681 interleukin-8 receptors Human genes 0.000 description 13
- 108010038415 interleukin-8 receptors Proteins 0.000 description 13
- 210000004303 peritoneum Anatomy 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 12
- 210000000265 leukocyte Anatomy 0.000 description 12
- 239000011347 resin Substances 0.000 description 12
- 229920005989 resin Polymers 0.000 description 12
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- 210000003038 endothelium Anatomy 0.000 description 11
- 102100026236 Interleukin-8 Human genes 0.000 description 10
- 102100036154 Platelet basic protein Human genes 0.000 description 10
- 210000001744 T-lymphocyte Anatomy 0.000 description 10
- 238000007792 addition Methods 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 239000003446 ligand Substances 0.000 description 10
- 101001027327 Bos taurus Growth-regulated protein homolog alpha Proteins 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 9
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 9
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 230000035605 chemotaxis Effects 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 210000004698 lymphocyte Anatomy 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 108010014419 Chemokine CXCL1 Proteins 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 229940114079 arachidonic acid Drugs 0.000 description 8
- 235000021342 arachidonic acid Nutrition 0.000 description 8
- 230000003399 chemotactic effect Effects 0.000 description 8
- 230000002209 hydrophobic effect Effects 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 7
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 7
- 239000012190 activator Substances 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 108010066822 low affinity platelet factor 4 Proteins 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000003389 potentiating effect Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- 101710195957 Platelet basic protein Proteins 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 210000002889 endothelial cell Anatomy 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 239000000178 monomer Substances 0.000 description 6
- 210000005259 peripheral blood Anatomy 0.000 description 6
- 239000011886 peripheral blood Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 239000003643 water by type Substances 0.000 description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 230000002924 anti-infective effect Effects 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 239000007790 solid phase Substances 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 102000000018 Chemokine CCL2 Human genes 0.000 description 4
- OZLGRUXZXMRXGP-UHFFFAOYSA-N Fluo-3 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(Cl)C(=O)C=C3OC3=CC(O)=C(Cl)C=C32)N(CC(O)=O)CC(O)=O)=C1 OZLGRUXZXMRXGP-UHFFFAOYSA-N 0.000 description 4
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 230000035508 accumulation Effects 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 4
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 4
- 238000012875 competitive assay Methods 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 208000027866 inflammatory disease Diseases 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000002953 preparative HPLC Methods 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 230000001052 transient effect Effects 0.000 description 4
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 3
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- YBAFDPFAUTYYRW-YUMQZZPRSA-N Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O YBAFDPFAUTYYRW-YUMQZZPRSA-N 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 101000582950 Homo sapiens Platelet factor 4 Proteins 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 3
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 3
- 102000016387 Pancreatic elastase Human genes 0.000 description 3
- 108010067372 Pancreatic elastase Proteins 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 230000008512 biological response Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 108010035886 connective tissue-activating peptide Proteins 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- UNXNGGMLCSMSLH-UHFFFAOYSA-N dihydrogen phosphate;triethylazanium Chemical compound OP(O)(O)=O.CCN(CC)CC UNXNGGMLCSMSLH-UHFFFAOYSA-N 0.000 description 3
- 238000009510 drug design Methods 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 230000028023 exocytosis Effects 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000003278 mimic effect Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 208000004235 neutropenia Diseases 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229960002429 proline Drugs 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000007115 recruitment Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 102000001902 CC Chemokines Human genes 0.000 description 2
- 108010040471 CC Chemokines Proteins 0.000 description 2
- 102000009410 Chemokine receptor Human genes 0.000 description 2
- 108050000299 Chemokine receptor Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- VSRCAOIHMGCIJK-SRVKXCTJSA-N Glu-Leu-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O VSRCAOIHMGCIJK-SRVKXCTJSA-N 0.000 description 2
- 206010018690 Granulocytosis Diseases 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- 108010092694 L-Selectin Proteins 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 2
- 102000016551 L-selectin Human genes 0.000 description 2
- 108010008211 N-Formylmethionine Leucyl-Phenylalanine Proteins 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- 101100491597 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) arg-6 gene Proteins 0.000 description 2
- 206010029379 Neutrophilia Diseases 0.000 description 2
- 208000005141 Otitis Diseases 0.000 description 2
- 241000282520 Papio Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 230000009809 T cell chemotaxis Effects 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- AMJRSUWJSRKGNO-UHFFFAOYSA-N acetyloxymethyl 2-[n-[2-(acetyloxymethoxy)-2-oxoethyl]-2-[2-[2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]-5-(2,7-dichloro-3-hydroxy-6-oxoxanthen-9-yl)phenoxy]ethoxy]-4-methylanilino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C2=C3C=C(Cl)C(=O)C=C3OC3=CC(O)=C(Cl)C=C32)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O AMJRSUWJSRKGNO-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000001254 matrix assisted laser desorption--ionisation time-of-flight mass spectrum Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000003593 megakaryocyte Anatomy 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
- MRTPISKDZDHEQI-YFKPBYRVSA-N (2s)-2-(tert-butylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC(C)(C)C MRTPISKDZDHEQI-YFKPBYRVSA-N 0.000 description 1
- NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 1
- PEMUHKUIQHFMTH-QMMMGPOBSA-N (2s)-2-amino-3-(4-bromophenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(Br)C=C1 PEMUHKUIQHFMTH-QMMMGPOBSA-N 0.000 description 1
- VVQIIIAZJXTLRE-QMMMGPOBSA-N (2s)-2-amino-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound CC(C)(C)OC(=O)NCCCC[C@H](N)C(O)=O VVQIIIAZJXTLRE-QMMMGPOBSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- NYPYHUZRZVSYKL-UHFFFAOYSA-N -3,5-Diiodotyrosine Natural products OC(=O)C(N)CC1=CC(I)=C(O)C(I)=C1 NYPYHUZRZVSYKL-UHFFFAOYSA-N 0.000 description 1
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 1
- FJQZXCPWAGYPSD-UHFFFAOYSA-N 1,3,4,6-tetrachloro-3a,6a-diphenylimidazo[4,5-d]imidazole-2,5-dione Chemical compound ClN1C(=O)N(Cl)C2(C=3C=CC=CC=3)N(Cl)C(=O)N(Cl)C12C1=CC=CC=C1 FJQZXCPWAGYPSD-UHFFFAOYSA-N 0.000 description 1
- DFPYXQYWILNVAU-UHFFFAOYSA-N 1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1.C1=CC=C2N(O)N=NC2=C1 DFPYXQYWILNVAU-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- VUCNQOPCYRJCGQ-UHFFFAOYSA-N 2-[4-(hydroxymethyl)phenoxy]acetic acid Chemical compound OCC1=CC=C(OCC(O)=O)C=C1 VUCNQOPCYRJCGQ-UHFFFAOYSA-N 0.000 description 1
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 1
- PZNQZSRPDOEBMS-QMMMGPOBSA-N 4-iodo-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(I)C=C1 PZNQZSRPDOEBMS-QMMMGPOBSA-N 0.000 description 1
- GTVVZTAFGPQSPC-UHFFFAOYSA-N 4-nitrophenylalanine Chemical compound OC(=O)C(N)CC1=CC=C([N+]([O-])=O)C=C1 GTVVZTAFGPQSPC-UHFFFAOYSA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 108091071248 Alpha family Proteins 0.000 description 1
- 102000040717 Alpha family Human genes 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 108091071247 Beta family Proteins 0.000 description 1
- 101800003265 Beta-thromboglobulin Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000208199 Buxus sempervirens Species 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 102000001327 Chemokine CCL5 Human genes 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 102000016951 Chemokine CXCL2 Human genes 0.000 description 1
- 108010014414 Chemokine CXCL2 Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 208000019872 Drug Eruptions Diseases 0.000 description 1
- 108010024212 E-Selectin Proteins 0.000 description 1
- 102100023471 E-selectin Human genes 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- NIGWMJHCCYYCSF-UHFFFAOYSA-N Fenclonine Chemical compound OC(=O)C(N)CC1=CC=C(Cl)C=C1 NIGWMJHCCYYCSF-UHFFFAOYSA-N 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 208000032678 Fixed drug eruption Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010018687 Granulocytopenia Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000012630 HPLC buffer Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- PGXZHYYGOPKYKM-IHRRRGAJSA-N His-Pro-Lys Chemical class C1C[C@H](N(C1)C(=O)[C@H](CC2=CN=CN2)N)C(=O)N[C@@H](CCCCN)C(=O)O PGXZHYYGOPKYKM-IHRRRGAJSA-N 0.000 description 1
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 1
- 101500025785 Homo sapiens IL-8(6-77) Proteins 0.000 description 1
- 101000973997 Homo sapiens Nucleosome assembly protein 1-like 4 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 102400001232 IL-8(6-77) Human genes 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 206010023347 Keratoacanthoma Diseases 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-Tryptophan Natural products C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 229930182844 L-isoleucine Natural products 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 244000137850 Marrubium vulgare Species 0.000 description 1
- 206010051676 Metastases to peritoneum Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 102400000569 Myeloperoxidase Human genes 0.000 description 1
- 108090000235 Myeloperoxidases Proteins 0.000 description 1
- 101100205189 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-5 gene Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000010362 Protozoan Infections Diseases 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- 230000010398 acute inflammatory response Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 239000003194 amino acid receptor blocking agent Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- WTOFYLAWDLQMBZ-LURJTMIESA-N beta(2-thienyl)alanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CS1 WTOFYLAWDLQMBZ-LURJTMIESA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- PRQROPMIIGLWRP-BZSNNMDCSA-N chemotactic peptide Chemical compound CSCC[C@H](NC=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-BZSNNMDCSA-N 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 201000004196 common wart Diseases 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960000415 diiodotyrosine Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940116441 divinylbenzene Drugs 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000001210 effect on neutrophils Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 208000012587 fixed pigmented erythema Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- UHBYWPGGCSDKFX-VKHMYHEASA-N gamma-carboxy-L-glutamic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 102000057550 human NAP1L4 Human genes 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 229940045505 klebsiella pneumoniae Drugs 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 108010034529 leucyl-lysine Proteins 0.000 description 1
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000037257 muscle growth Effects 0.000 description 1
- 230000003039 myelosuppressive effect Effects 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 208000010918 peritoneal neoplasm Diseases 0.000 description 1
- CMCWWLVWPDLCRM-UHFFFAOYSA-N phenidone Chemical compound N1C(=O)CCN1C1=CC=CC=C1 CMCWWLVWPDLCRM-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- BAZAXWOYCMUHIX-UHFFFAOYSA-M sodium perchlorate Chemical compound [Na+].[O-]Cl(=O)(=O)=O BAZAXWOYCMUHIX-UHFFFAOYSA-M 0.000 description 1
- 229910001488 sodium perchlorate Inorganic materials 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000003868 tissue accumulation Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 201000006382 tuberculoid leprosy Diseases 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5421—IL-8
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to polypeptide analogs of the human cytokine interleukin 8 that function as agonists or antagonists of interleukin 8 and other human alpha chemokines.
- the invention also provides methods of using these peptide analogs to augment or inhibit various biological responses associated with alpha chemokines.
- Interleukin 8 is a human cytokine that promotes the recruitment and activation of neutrophil leukocytes and represents one of several endogenous mediators of the acute inflammatory response. In the past it was variously termed neutrophil-activating factor, monocyte-derived neutrophil chemotactic factor, interleukin-8 (IL-8) , and neutrophil-activating peptide- 1, (NAP-1) .
- the term IL-8 has gained the widest acceptance and will be used herein.
- IL-8 monomer The most abundant naturally occurring form of the IL-8 monomer is a 72-residue protein apparently derived by processing of a 99-residue precursor.
- Other proteins with related sequences, including neutrophil- activating peptide-2 and GROCK (with melanoma growth stimulatory activity) are IL-8 homologues which have neutrophil-activating properties.
- IL-8 is a member of the chemokine superfamily that is divided into two distinct functional classes: alpha (o.) and beta (3) .
- the members of each class share an organizing primary sequence motif.
- the a members are distinguished by a C-X-C motif with the first two cysteines in the motif separated by an intervening residue.
- C-X-C chemokines are potent chemoattractants and activators for neutrophils, and are represented by IL-8.
- the jS family chemokines have a C-C motif and are equally potent chemoattractants and activators of monocytes.
- chemokine family has clearly defined functions: the C- X-C subfamilies cannot activate monocytes while the C-C subfamily has no effect on neutrophils. Although these two families of chemokines have similar three dimensional structures, they demonstrate fairly low sequence homology (30 to 35%) . Proteins within the same family, such as platelet factor four (PP-4) , are structurally related to IL-8 (35% sequence identity) but lack the N terminal ELR sequence (Glu-Leu-Arg) which has been shown by site directed mutagenesis to be critical for IL-8 activity. Thus, PF-4 has an entirely different profile of biological activity.
- PP-4 platelet factor four
- Inflammation and autoimmune responses are initiated by leukocytes which migrate out of the microvasculature and into the extravascular space in response to chemoattractant molecules.
- chemoattractants may be released from the host and include cytokines and activated complement components. Alternatively, they may be released from an invading organism (e.g., N-formylated peptides or MDP dipeptide) . Once exposed to chemoattractants within the vasculature, the leukocytes become activated and capable of adhering to the endothelium, providing the first step in the development of inflammation.
- Stimulated neutrophils adhere to the endothelium of the microvasculature in response to a gradient of chemoattractants which direct the cells into the extravascular space toward the source of the chemoattractant.
- the endothelium After stimulation with cytokines or bacterial products, the endothelium arrests leukocytes as they traverse (roll along) the microvasculature near sites of inflammation. After being forced to stop in the microvasculature, the leukocytes are then activated to adhere more tightly to the endothelium and to migrate to the abluminal aspect of the vessel. The leukocyte, once it is out of the blood vessel, is then capable of following a gradient of chemoattractants toward the exciting pathogen.
- Vascular endothelium activated by stimulants such as IL-1, IL-8, TNF, or LPS, appears to play a pivotal role in this process through the production of pro-inflammatory substances, including chemoattractants and cytokines such as chemokines.
- the inflammatory properties of IL-8 were initially demonstrated from a purified natural product injected intradermally into rabbits (Rampart, M. et al. , Am. J. Path. 125. (1) :21-25, 1989) . More recently, neutralizing antibodies to human IL-8 were shown to have a protective effect in inflammatory lung injury in rats.
- neutrophilia Shortly thereafter neutrophilia, a characteristic of IL- 8, is observed.
- the neutrophilia likely reflects recruitment of mature PMNs to a marginal pool in the lung and other organs as well as immature PMNs from the marrow.
- Endothelial cells can exert both proinflammatory and anti-inflammatory effects by virtue of the mediators they generate. Endothelial cells can be stimulated to generate IL-8, but unlike other mediators, IL-8 may be released from the endothelial cell. Alternatively, endothelial cell produced IL-8 is an important chemoattractant and activator of neutrophils .
- IL-8 can bind to endothelial cells, causing a local activation of the endothelium that results in the ability of this altered endothelium to attract neutrophils that have come into contact with the (activated) endothelium.
- IL-8 initially functions as a proinflammatory cytokine, whereas its continued generation and release from the endothelium ultimately causes a down regulation of neutrophils, with a curtailment in their further recruitment. Whether the cell associated IL-8 or released IL-8 provides the vital contribution to the outcome of the inflammatory response remains unresolved.
- IL-8 receptors are "promiscuous" and respond with a calcium flux when bound by structurally related ligands with the following order of potency: IL-8 > MGSA > NAP-2. The order of potency correlates with the effectiveness of these compounds in binding to neutrophils during competitive binding assays with the radio-labeled IL-8.
- C5a a structurally related chemoattractant that is similar in size and charge to IL- 8 and which has a receptor in the same family, does not activate the IL-8 receptor.
- IL-8 appears to bind to at least one class of receptor sites on neutrophils with a frequency of approximately 64,000/cell and a K ⁇ , of 0.2 nM.
- IL-8 The three-dimensional structure of IL-8 is known by two-dimensional NMR and x-ray diffraction techniques.
- the IL-8 monomer has antiparallel ⁇ strands followed by a single overlying COOH-terminal ⁇ ; helix.
- Two disulfide bridges, between cysteines 7 and 34, and between cysteines 9 and 50 seem to stabilize the tertiary structure.
- Residues 1-6 and the loop residues 7-18 seem to have little defined secondary structure.
- IL-8 is a noncovalent homodimer which is stabilized primarily by interactions between the ⁇ strands of the two monomers.
- Interleukin-8 has shown both anti-tumor and anti-infective therapeutic activity. IL-8 has been shown to induce the regression of macroscopic tumors in a model of peritoneal carcinomatosis in the rat. In this model, IL-8 was shown to recruit PMN to the challenge site but did not enhance PMN infiltration of the tumor or the cytotoxic activity of PMN. Regardless, it did have significant therapeutic activity which may be secondary to PMN cytotoxicity and associated with other intermediate cells. It is suggested that lymphocytes could be involved since IL-8 has also demonstrated the ability to stimulate T-cell chemotaxis. (Lejeune, P., et al. , Cancer Immunol. Immunotherapy. 3.8:167-170, 1994). Similarly, Interleukin-8 has shown therapeutic activity in nonneutropenic mice who received IL-8 shortly before challenge and at the site of infectious challenge with either P. aeruginosa, Klebsiella -pneumoniae, or
- IP-10 an alpha chemokine whose secretion is induced by IFN- ⁇ and LPS, was genetically engineered into tumor cells.
- the expression of IP-10 by several tumor cell lines had no effect on the growth of these tumor cells in vi tro but elicited a powerful host mediated anti-tumor effect in vivo.
- tumors genetically engineered to secrete IP-10 elicited a T-lymphocyte dependent anti-tumor response resulting in the rejection of tumors in vivo. Animals injected with these tumor cells do not develop tumors or develop tumors which spontaneously regress.
- administration of parental tumor cells admixed with IP-10 secreting tumor cells do not give rise to tumors in experimental animals.
- alpha chemokines may also act as T-cell adjuvants and therapeutics via T-cell chemotaxis and/or augmentation (Luster, A.D., J..Exp. Med. 178.:1057-1064, 1993). Because of its demonstrated anti-tumor and anti-infective activities, considerable interest exists in developing specific IL-8 agonists as immune adjuvants and anti-tumor agents for treatment of immunocompromised patients or patients with various forms of cancer.
- One strategy for developing agonists is to prepare polypeptide analogs which correspond to the known or suspected binding domains of naturally occurring IL-8 and related alpha chemokines. Such analogs are often found capable not only of binding to a cognate receptor, but of stimulating a desired biological response, such as anti- tumor activity for IL-8.
- IL-8 is also a key mediator of inflammatory diseases
- substances capable of blocking or interrupting the activity of IL-8 for use in anti- inflammatory compositions may prove to be advantageous over presently available NSAID's, steroid based anti-inflammatory drugs and cytotoxic drugs which often have severe side-effects with the continued usage that is required for chronic inflammatory diseases. It would also be desirable to identify IL-8 analogs having an increased inflammatory activity for medical research applications.
- IL-8 has been previously produced through chemical synthesis (Clark-Lewis, et al. , Biochemistry 30: 3128-3135, 1991) and by recombinant DNA methods (Herbert, et al., J. Biol. Chem. 286: 18989-18994, 1991).
- IL-8 exists in several forms that vary at the NH 2 -terminus, which have been detected in preparations purified from natural sources.
- the present invention involves low molecular weight peptides which have agonistic or antagonistic activity for IL-8 or other alpha chemokines.
- the peptide agonists have an amino acid sequence with the following formula:
- Xaa 2 is lie, or Val;
- Xaa 3 is Lys, Gin, or Ser;
- Xaa 4 is Thr, or lie;
- Xaa 5 is Tyr, Leu, Met, His, Val, or Thr;
- Xaa 6 is Ser, Gin, Thr, or Ala;
- Xaa 7 is Lys, Arg, or His;
- Xaa 8 is absent or is Pro, Phe, or Gly;
- Xaa 9 is absent or is Phe, lie, or Val;
- Xaa 10 is absent or is His, Lys, or Arg;
- Xaa ⁇ is absent or is Pro, Leu, or Phe; and Xaa 12 is absent or is Lys, His or Arg.
- a preferred embodiment of the present invention comprises an amino acid sequence with agonist activity substantially equivalent to Glu- Leu-Arg-Cys-Gln-Cys-Ile-Lys-Thr-Tyr-Ser-Lys-Pro-Phe-His- Pro-Lys as well as similar analogs having additional N- terminal amino acids.
- These polypeptides act as anti- cancer and anti-infective agents for the therapy of leukemia and solid tumors and metastatic disease.
- These embodiments also have anti-infective therapeutic activity for viral, bacterial, fungal, yeast and parasitic infections.
- the polypeptide is modified selectively to provide additional agonists of IL-8.
- IL-8 agonists may include peptides truncated by 3 amino acid residues at the C terminus by deletion.
- agonists for IL-8 or other alpha chemokines include cysteine substitutions by aminobutyric acid, homocysteine or diaminosuberic acid.
- the inventor herein has investigated several low molecular weight peptide analogs of IL-8 with biological activity that substantially compete for IL-8 binding and are based on IL-8 sequences. Truncation of native IL-8, particularly in the C-terminal region thereof, yields IL-8 peptidal mimetics having the therapeutically useful properties of anti-neoplastic and anti-infective drugs. More particularly, the IL-8 low molecular weight peptide analogs of the present invention comprise an amino acid sequence with biological activity substantially equivalent to the IL-8 sequence beginning at residue 4 and continuing through residue 20, wherein at least the N-terminal residues found to be critical for neutrophil binding and stimulation, i.e., Glu-4, Leu-5, Arg-6 are contained at the N-terminal region.
- IL-8 analogs include an additional two or three residues at the amino terminus of the 20 residue peptide so as to provide the 1-20 forms that are also useful as IL-8 agonists.
- significant biological activity is associated with low molecular weight peptide analogs from residue 4-17. The resulting in a 13 amino acid peptide also has agonist activity for IL-8.
- this invention provides a biologically active human IL-8 low molecular weight peptide analog having an amino acid sequence substantially equivalent to the IL-8 polypeptide, beginning at residue 4 and continuing to residue 17 or 20.
- IL-8 peptide analogs with antagonistic activity have also been synthesized. These peptide analogs are comprised of an amino acid sequence substantially equivalent to those described above, except lacking the N-terminal pair of residues (i.e., Glu-Leu) .
- the antagonist analogs compete strongly with IL-8 for neutrophil binding without signal transduction, due to the deletion of Glu-Leu (two-thirds of the "ELR" motif required for signal transduction activity) .
- the peptide comprises the sequence: Arg-Cys-Gln-Cys-Ile-Lys-Thr-Tyr-Ser-Lys- Pro-Phe-His-Pro-Lys as well as similar analogs having either one or two additional N-terminal amino acids.
- antagonists that compete with IL-8 yet still retain antagonist properties are obtained by replacing residues Glu and Leu with non-polar amino acids, such as Ala, Val or Leu.
- the IL-8 sequence is truncated from residue 21 to the C-terminus as well at N-terminal residues 1 to 5.
- the antagonist analogs which contain the N-terminal residues found to be critical for neutrophil binding and stimulation, i.e., Arg 6, begin at residue 6 and continue through residue 20.
- IL-8 analogs have also been synthesized that include an additional one or two non-polar residues at the amino terminus of the 14 residue peptide so as to provide the 4 or 5-20 forms that are also useful as IL-8 antagonists.
- significant biological activity is associated with low molecular weight peptide analog from residue 6-17 resulting in a 12 amino acid peptide with antagonist activity for IL-8.
- this invention also provides a human interleukin-8 low molecular weight peptide analog with antagonist activity having an amino acid sequence substantially equivalent to those found at the N-termini of native IL-8, i.e., amino acids 6 through 20 or 6 through 17. Further, equal or greater activity is associated with the addition of Ala, Val, Leu or other amino acid at residue 4 and 5.
- This invention also provides methods of use of these agonistic and antagonistic peptide analogs of human IL-8 both in vivo and in vi tro.
- the embodiments of the present invention are related to low molecular weight peptide analogs of IL-8 which are less than 30, more preferably less than 20, and most preferably 11 to 17 amino acids in length. This shorter length allows for more rapid and extensive tissue distribution of the drug on administration as compared to a 70 amino acid therapeutic. Further, this invention substantially increases the purity of the product through reduced errors inherent to the manufacture of a large protein. In addition, this invention has a significant reduction in the cost of goods as compared to the invention in the aforementioned patent.
- both sequence and three dimensional, agonists and antagonists for both known and additional alpha chemokines can be derived based on the present invention.
- the present claims include information on the reduction to practice of an invention specific for the IL-8 ligand and receptor.
- Figure 1 FACS analysis profiles of Ca + release from polymorphonuclear monocytes (PMNs) , unstimulated (Fig. 1A) or stimulated with native IL-8 (Fig. IB) .
- PMNs polymorphonuclear monocytes
- Fig. 1A unstimulated
- Fig. IB native IL-8
- FIG. 2 FACS analysis profiles of Ca + release from untreated (Fig. 2A) and PBS treated (Fig. 2B) PMNs.
- Figure 3 FACS analysis profiles of Ca + release from untreated (Fig. 3A) and analog 1 treated PMNs (Fig. 3B) .
- FIG. 4A FACS analysis profiles of Ca + release from untreated PMNs (Fig. 4A) and PMNs treated with IL-8 and analog 12.
- Figure 5 A graph of a dose response curve showing the chemotactic effects of a single i.p. injection of analog 1 in increasing concentrations.
- X axis represents the dose of analog 1 in ⁇ g/animal;
- Y axis depicts cell number x 10 6 in the peritoneum.
- Figure 6 A graph of a dose response curve showing the chemotactic effects of a single i.p. injection of analog 1 in increasing concentrations.
- X axis represents the dose of analog 1 in ⁇ g/animal;
- Y axis depicts cell number x 10 6 in the peripheral blood.
- Figure 7 A graph showing the different cell types present in the peritoneum in response to increasing amounts of i.p. injected analog 1.
- the X axis represents the dose of analog 1 in ⁇ g/animal;
- the Y axis represents cell number x 10 6 in the peritoneum. • lymphocytes;
- Figure 8 A graph showing the absolute cell number of different cell types present in the peritoneum after an i.p. injection of analog 1.
- the X axis represents the dose of analog 1 in ⁇ g/animal;
- the Y axis represents cell number x 10 6 in the peritoneum. • lymphocytes; ⁇ PMNs; A monocytes.
- Figure 9 A graph showing the different cell types present in the peripheral blood after a single i.p. injection of analog 1.
- the X axis represents the dose of analog 1 in ⁇ g/animal .
- the ratio of lymphocytes to PMNs is shown on axis Yl; the number of monocytes is shown on Y2. • lymphocytes; ⁇ PMNs; A monocytes.
- Figure 10 A graph showing the absolute cell number of different cell types present in the peripheral blood after a single i.p. injection of analog 1.
- the X axis represents the dose of analog 1 in ⁇ g/animal.
- the ratio of lymphocytes to PMNs is shown on axis Yl; the number of monocytes is shown on Y2. • lymphocytes; ⁇ PMNs; A monocytes.
- Figure 11 A graph showing the kinetics of the in vivo chemotactic response in the peritoneum following an i.p. injection of 10 ⁇ g of analog 1.
- the X axis represents time in hours and the Y axis represents the absolute cell number. • lymphocytes; ⁇ PMNs; A monocytes.
- Figure 12 A graph showing the effects of increasing doses of analog 12 on arachidonic acid induced ear inflammation in mice.
- the X axis represents increasing doses of analog 12 in ⁇ g/animal .
- the Y axis represents ear thickness measured in units of .001 inches .
- Figure 13 Graphs of competitive binding assays showing the ability of peptide analogs to displace radiolabled IL-8 from the IL-8 receptor.
- the X axis represents increasing molar amounts of analog.
- the Y axis shows the % of total binding.
- the analogs tested are as follows: 13A XXR, Sequence I.D. No. 12; 13B CVC, Sequence I.D. No. 23; 13C CMC, Sequence I.D. No. 24; 13D FH, Sequence I.D. No. 25.
- Figure 14 Graphs of competitive binding assays showing the ability of peptide analogs to displace radiolabled Gro ⁇ from the IL-8 receptor.
- the X axis represents increasing molar amounts of analog.
- the Y axis shows the % of total binding.
- the analogs tested are as follows: 13A XXR, Sequence I.D. No. 12; 13B CVC, Sequence I.D. No. 23; 13C CMC, Sequence I.D. No. 24; 13D FH, Sequence I.D. No. 25.
- biological activity is a function or set of functions performed by a molecule in a biological context (i.e., in an organism or an in vi tro surrogate or facsimile model) .
- biological activity is characterized by chemotactic activity (preferably PMNs but may also include T lymphocytes and/or monocytes/macrophages) . It may also include second messenger and/or increases in elastase activity by PMNs.
- a low molecular weight peptide analog This identifies a natural or mutant (mutated) analog of a protein (generally less then 20-30 residues in length, comprising a linear or discontinuous series of fragments of that protein which may have one or more amino acids replaced with other amino acids and which has altered, enhanced or diminished biological activity when compared with the parent or non-mutated protein.
- Substantially equivalent biological activity - is that profile of activity which defines IL-8 or other alpha chemokines. In in vitro surrogate models this may include chemotaxis of PMNs, T lymphocytes or monocytes; Ca ++ signal transduction; or increases in elastase activity. In vivo this would be defined as the chemotaxis of PMNs to a localized site for example the peritoneum following i.p. injection or to the peripheral blood.
- Substantially or essentially equivalent peptide analogs An analog is essentially equivalent to another if it has one or more of the biological activities characteristic of human IL-8, essentially has the same number of amino acids as the analog specified in Tables 2 and 3 with no more than two additions or deletions and, in comparison with the sequence of the specified analog, has at most five amino acid substitutions, all of which would be considered neutral in the art (i.e., acidic for acidic, basic for basic, uncharged polar for uncharged polar, hydrophobic for hydrophobic, and the like) .
- composition comprising short polypeptide analogs of IL-8 or related alpha chemokines that bind to cellular chemokine receptors and act as agonists or antagonists of IL-8 or other alpha chemokines.
- polypeptide analogs generally correspond to the amino-terminal domain of IL-8 or related chemokines, as described in greater detail herein.
- the complete amino acid sequence of naturally- occurring IL-8 has been published (Clark-Lewis et al., J. Biol. Chem. 269: 16075-16078, 1994); the twenty amino acid residues comprising the amino-terminal domain is set forth below as Sequence I.D. No.
- Asx means Asp or Asn
- Glx eans Glu or Gin
- the present invention includes peptide sequences with agonist activity having the following formula:
- Xaa ! is Gin, Met, or Val; Xaa 2 is lie, or Val; Xaa 3 is Lys, Gin, or Ser; Xaa 4 is Thr, or lie;
- Xaa 5 is Tyr, Leu, Met, His, Val, or Thr;
- Xaa 6 is Ser, Gin, Thr, or Ala;
- Xaa 7 is Lys, Arg, or His;
- Xaa 8 is absent or is Pro, Phe, or Gly;
- Xaa 9 is absent or is Phe, He, or Val;
- Xaa 10 is absent or is His, Lys, or Arg;
- Xaa n is absent or is Pro, Leu, or Phe; and
- Xaa 12 is absent or is Lys, His or Arg.
- Alpha Chemokine - IL-8 also called NAP-1 Glu-Leu-Arg- ⁇ Zys-Gln-Cys-lie-Lys-Thr-Tyr-Ser-Lys-Pro-
- Analog 5 (Sequence I.D. No. 5) : Derived from Alpha Chemokine - GRO Glu-Leu-Arg-Cys-Gln-Cys-Leu-Gln-Thr-Met-Thr-Gly-Val- His-Leu-Lys
- Analog 6 (Sequence I.D. No. 6): Derived from Alpha Chemokine - GRO-7 (also called MIP-23)
- Alpha Chemokine-3 thromboglobulin also called NAP-2
- Analog 8 (Sequence I.D. No. 8) : Derived from Alpha Chemokine - 9E3
- Analog 11 Derived from Alpha Chemokine - ENA-78 Glu-Leu-Arg-Cys-Val-Cys-Leu-Gln-Thr-Thr-Gln-Gly-Val- His-Pro-Lys
- Analog 15 (Sequence I.D. No. 15) : Derived from Alpha Chemokine - GRO-3 (also called MIP-2 ⁇ )
- Analog 16 (Sequence I.D. No. 16): Derived from Alpha Chemokine - GRO
- Analog 19 Derived from Alpha Chemokine - 9E3 Arg-Cys-Gln-Cys-Ile-Ser-Thr-His-Ser-Lys-Phe-He-His- Pro-Lys
- Analog 20 (Sequence I.D. No. 20): Derived from Alpha Chemokine - 310C
- Analog 21 (Sequence I.D. No. 21) : Derived from Alpha Chemokine - CNC Arg-Cys-Gln-Cys-Leu-Gln-Thr-Val-Ala-Gly-He-His-Phe- Lys Analog 22 (Sequence I.D. No. 22) :
- CVC Derived from IL-8 (this analog is sometimes referred to herein as "CVC")
- the present invention includes analogs that are essentially equivalent to any analog of the invention, as specified in Tables 2 and 3.
- an analog is essentially equivalent to one specified above if it has one or more of the biological activities characteristic of human IL-8, essentially has the same number of amino acids as the analog specified in Tables 2 and 3 with no more than two additions or deletions and, in comparison with the sequence of the specified analog, has at most five amino acid substitutions, all of which would be considered neutral in the art (i.e., acidic for acidic, basic for basic, uncharged polar for uncharged polar, hydrophobic for hydrophobic, and the like) .
- the acidic amino acids are Asp, Glu and gammacarboxyglutamic acid.
- the basic amino acids are Arg, Lys, His and Orn.
- the hydrophobic amino acids are Ala He, Leu, Met, Nor, Phe, Trp, Tyr, Val, t- butylglycine, norvaline, cyclohexylalanine, t- butylalanine, amino-4phenybutyric acid, beta-2-thienylala nine, p-bromophenylalanine, p-chlorophenylalanine, p- iodophenylalanine, p-nitrophenylalanine, 3.5- diiodotyrosine, phenylglycine, and napthylalanine.
- Uncharged polar amino acids are Asn, Gin, Ser, and Thr. Gly can be substituted for an uncharged polar or a hydrophobic amino acid, but substitutions with Pro are avoided because helical structures may be destabilized by such a significant effect on secondary structure of inserting a Pro in place of another
- substitutions with Cys are specified and may include substitution with o.-aminobutyric acid (Aba) .
- This non-natural amino acid is suggested to cause a super-imposition with cysteine. Its ethyl side chain is closer to being isoteric than any of the naturally occurring non-polar amino acids.
- Cys can be substituted with homocysteine or diaminosuberic acid thereby retaining charge and size conformation but eliminating potential homodimerization.
- the chiral amino acids of the IL-8 analogs of the present invention have the L configuration.
- Analog 1 (Sequence I.D. No.
- Analog 1 was designed as a structural mimic of IL-8 from amino acid residues 4 to 20 (Clark-Lewis et al., 1994, supra).
- Analog 1 contains overall homology with the amino acid sequence of human IL-8.
- Analog 2 (Sequence I.D. No. 2) was designated as a structural mimic of human IL-8 from amino acid residues 4 to 17.
- Analog 2 which has been C-terminally truncated has a slight loss of activity when compared to analog 1.
- Analog 12 (Sequence I.D. No. 12) was designed as a structural mimic of IL-8 from amino acid residues 6 to 20.
- Analog 12 contains overall homology with the amino acid sequence of human IL-8.
- Analogs 13 and 25 (Sequence I.D. Nos. 13 and 25) were designated as structural mimics of human IL-8 from amino acid residues 6 to 17 (or 18) . Analog 13 has been C-terminal truncated causing a slight loss of activity when compared to analog 12.
- An analog of the present invention can be made by exclusively solid phase techniques, by partial solid- phase techniques, by fragment condensation, by classical solution coupling, or, as long as the analog consists of only amino acids among the twenty naturally occurring amino acids corresponding to codons of the genetic code, by employing recombinant DNA techniques with bacteria, such as E. coli or B . subtilis; yeast, such as S. cerevisiae or P.pastoris; or insect or mammalian cells.
- IL-8 analogs encompassed by the present invention have one or more of the biological activities of naturally occurring IL-8, as described above, and, as such, are useful therapeutically in one or more of the ways in which IL-8 is known to be useful, e.g., as an anti-infective for bacterial, fungal, viral, and or protozoan infections, as an anti-neoplastic for both leukemia and solid or metastatic disease.
- the biological activity of an analog of the invention is determined by comparing the analog with naturally occurring IL-8.
- the analogs of the invention are employed therapeutically, under the guidance of a physician for the treatment of leukemic or solid tumors or metastatic disease and infectious diseases including but not limited to viral, bacterial, fungal, yeast or parasitic. They may also be used for the treatment of anti-inflammatory and auto immune disease. Disorders in this group include SLE, GVHD, RA, IBD, asthma and psoriasis.
- the dose and dosage regiment of an analog according to the invention that is suitable for administration to a particular patient can be determined by a physician considering the patient's age, sex, weight, general medical condition, and the specific condition and severity thereof for which the analog is being administered.
- the physician must also determine the route of administration of the analog; the pharmaceutical carrier with which the analog may be combined; and the analog's biological activity, relative to that of naturally occurring human IL-8, in the above- described assays.
- injection intavenous, subcutaneous or transmuscular
- injection of 1-500 ⁇ mol of analog/kg body weight
- bolus injection by bolus injection, by infusion over a period of about 5 minutes to about 60 minutes, or by continuous infusion
- Aerosol inhalation of 0.1 or 2 mg of analog/kg body weight is also sufficient for efficacy.
- Intravenous, subcutaneous or intramuscular administration is preferred for use of the analogs of the invention in treatment of neoplastic, infectious, autoimmune or inflammatory diseases.
- analogs of the invention can be combined, over a wide concentration range (e.g., 0.001 to 11.0 wt %) with any standard pharmaceutical carrier (e.g., physiological saline, THAM solution, or the like) to facilitate administration by any of various routes including intravenous, subcutaneous, intramuscular, oral, or intranasal, including by inhalation.
- any standard pharmaceutical carrier e.g., physiological saline, THAM solution, or the like
- compositions of the analogs of the invention can be prepared with any of a variety of inorganic or organic acids, such as for example, sulfuric, phosphoric, hydrochloric, hydrobromic, nitric, citric, succinic, acetic, benzoic and ascorbic.
- the analogs can, for example, be advantageously converted to the acetate salt by dissolution in an aqueous acetic acid solution (e.g., 10% solution) followed by lyophilization.
- compositions containing a compound of the present invention as the active ingredient in intimate admixture with a pharmaceutical carrier can be prepared according to conventional pharmaceutical compounding techniques.
- the carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., intravenous, oral or parenteral.
- any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like in the case of oral liquid preparations (such as, for example, suspensions, elixirs and solutions) ; or carriers such as starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations (such as, for example, powders, capsules and tablets) . Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form in which case solid pharmaceutical carriers are obviously employed.
- tablets may be sugar-coated or enteric-coated by standard techniques.
- the carrier will usually comprise sterile water, though other ingredients, for example, to aid solubility or for preservative purposes, may be included.
- injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed.
- the pharmaceutical compositions will generally contain dosage unit, e.g., tablet, capsule, powder, injection, teaspoonful and the like, from about 0.001 to about 10 mg/kg, and preferably from about 0.01 to about 0.1 mg/kg of the active ingredient.
- peptides that have a carboxyl group at the carboxy-terminus p-chloromethyl-derivatized polystyrene supports are employed, and the carboxy-terminal amino acid is esterified to the support via reaction with KF.
- Analogs with a C-terminal proline or a penultimate C- terminal proline may be synthesized using a 2- chlorotrityl chloride derivatized resin. Attachment of FMOC amino acids to the resin can be quantitated by spectrophotometric determination at 266 nm following treatment of a weighed sample with 50% piperidine in DMF. Substitution levels for automated syntheses are preferably between 0.2 and 0.6 mmol amino acid per g resin.
- FMOC 9-Fluorenyl methoxycarbonyl
- Side- chain functionalities were protected as follows: Arg with 4-Phenylazobenzyloxycarbonyl; Cys, Gin, and His with trityl; Glu, Ser, and Thr with benzyl; Lys with tertiary butyloxycarbonyl; and Tyr with tertiary butyl.
- Resins employed in the syntheses were purchased with the C-terminal residue already attached to derivatized polystyrene-1% divinyl-benzene (200-400 mesh) , either by 4-hydroxymethylphenoxyacetic acid or 2- chlorotrityl chloride.
- NMP N-Methylpyrrolidone
- HBTU 2 - (lH-benzotriazol-1-yl ) - 1 , 1 , 3 , 3 * tetramethyluronium hexafluorophosphate
- HPLC buffer systems which may be employed in the analytical HPLC include triethylamine phosphate (TEAP), pH 2.5-3.0, TEAP, pH 6.5, and a mixture of 0.1% phosphoric acid, 0. IM sodium perchlorate, pH 2.5 with an acetonitrile gradient. Although the TFA buffer system does not resolve microheterogeneous contaminants as well as other systems, recovery is generally 50-90% higher. A portion of a fraction from the preparative HPLC which appeared homogenous by analytical HPLC was removed, lyophilized and hydrolyzed for amino acid analysis.
- Analog 1 peptide-resin and 0.8 g of Analog 12 peptide- resin were obtained. These were added to 10 ml of TFA in two 100 ml round bottom flasks with 500 ⁇ l of H 2 0 500 ⁇ l thioanisole, 250 ⁇ l ethanedithiol and 750 mg phenol and stirred at 25 °C for 2 hours. The reactions were terminated by the addition of 100 ml cold diethyl ether to precipitate the peptides. The solution was filtered and the peptides were extracted with 100 ml 10% acetic acid in water, frozen, and lyophilized.
- Erythrocytes were removed by 6% dextran sedimentation for 30 minutes at room temperature, and then the supernatant was subjected to Ficoll (Ficoll-Paque, Pharmacia LKB, Uppsala, Sweden) density gradient centrifugation. PMNs were obtained from the pellet. Contaminated erythrocytes were eliminated by one cycle of hypotonic lysis. After an additional washing step, the cells were counted and adjusted to a final concentration of 5xl0 6 /ml in RPMI 1640 (Gibco, Grand Island, NY) .
- Ficoll Ficoll-Paque, Pharmacia LKB, Uppsala, Sweden
- Fluo-3 Loading The loading procedure with Fluo-3 (Molecular Probes, Eugene, OR) was carried out with PMNs suspended at a density of 5xl0 6 /ml in fresh RPMI 1640 containing 2.0 ⁇ M Fluo-3 AM (prediluted in dimethyl sulfoxide; Sigma Chemicals) in polypropylene tubes (Falcon 2063, Becton Dickinson) . PMNs were incubated for 25 minutes at 37 °C in a 5% C0 2 incubator. During the incubation period, the PMNs were gently agitated twice.
- FIG. 1 shows agonist activity on PMNs: Prior studies of IL-8/NAP-1 have demonstrated that this cytokine induces an increase in Ca + after stimulation of neutrophils.
- Figure IB demonstrates the effect of the 77 amino acid IL-8 at 10 "6 M on neutrophil Ca + release as measured and described above.
- Figure 1A shows unstimulated neutrophils.
- Figure 2A again shows unstimulated neutrophils whereas Figure 2B shows the lack of effects by the excipient alone.
- Treatment with Analog 1 induced a change in neutrophil Ca + concentration as shown in Figure 3B relative to untreated cells in Figure 3A. The data show that the majority of neutrophils showed an essentially identical increase in calcium concentration upon addition of either IL-8/NAP-1 or Analog 1.
- Analog 12 exhibits antagonist activity on PMNs: As shown in figure IB, treatment of neutrophils with native IL-8/NAP-1 leads to an increase of arbitrary fluorescence units as compared to excipient treated Fluo-3 loaded neutrophils (figure 2B) . However, as shown in Figure 4B, when the PMN's were pre-incubated with both native IL-8 and analog 12 at 10 "6 M, analog 12 blocked the appearance of the Ca + signal induced by IL-8 as shown in Figure IB.
- mice used for the study were C57BL/6 females, which were obtained from Jackson Laboratories. The animals were 8-10 weeks of age and weighed 15-18g. The mice were housed in conventional cages, fed pelleted food and given water ad libi tum.
- mice were bled from the retinal orbital plexus and the blood (40 ⁇ l) was collected into heparinized capillary tubes. The blood was then analyzed using a Serona Baker 9000 Blood analyzer. In addition, blood films were made and differentials undertaken on at least 200 cells/sample.
- mice were sacrificed by ether overdose, the ventral skin reflected and the peritoneum lavaged with three 5 ml lavages of calcium-, magnesium-free HBSS. At one, two, four, eight and 24 hours, following injection, three to five mice and/or control mice were lavaged and the cells collected in 15 ml tubes. The peritoneal cells were then centrifuged and counted. In addition, a differential was done on the peritoneal cells in a cytospin preparation. For the cytospin, 25 ⁇ l of bovine albumin (Sigma Lot #70H0183) was first placed in the bottom of the chamber, and 100 ⁇ l of cell suspension (100,000 cells) added.
- bovine albumin Sigma Lot #70H0183
- the chambers were spun at 1000 rpm for 5 minutes and left to dry. They were then placed in leukostat fixative solution for 5 seconds followed by 45 seconds in Leukostat solution 1 and 45 seconds in Leukostat solution 2. Fixed cells were washed in deionized H 2 0 for 5 seconds and allowed to dry. The slides were analyzed under a microscope for differentials.
- Analog 1 is an agonist with biological activity in in vivo assays.
- the in vivo chemotactic activity for cells into both the peritoneum and PBL are shown in this data set.
- Figure 5 shows the effect of a single i.p. injection of Analog 1 on peritoneal cellularity when employed in increasing concentrations from 0.1-500 ⁇ g/animal. Optimal activity was observed at 10 ⁇ g/animal.
- a significant increase in PBL cellularity ( Figure 6) was observed with maximal activity at 0.1 and 10 ⁇ g/animal.
- the primary cell type elicited in the peritoneum by the i.p. injection of Analog 1 was PMNs as shown in Figure 7.
- Analog 1 Treatment with Analog 1 resulted in a four-fold increase in PMNs in the peritoneum and an almost two-fold increase in monocyte/macrophages (Figure 8) . Similarly, there was an increase in the frequency of PMNs in the peripheral blood ( Figure 9) with a concomitant significant increase in the absolute number of PMNs and monocytes in the peripheral blood ( Figure 10) .
- Figure 11 shows the kinetics of the in vivo chemotactic response in the peritoneum following i.p. injection of 10 ⁇ g of this peptidal low molecular weight analog. As mentioned previously, the greatest increase observed was in the number of macrophages and PMNs in the peritoneum.
- IL-8 induced a neutrophil accumulation that was fast in onset, relatively short in duration and was associated with a parallel time course of plasma protein extravasation (Rampart, M. , Am. J. Pathol. 135-.21-25, 1989).
- the polypeptide Analog 1 of the present invention elicits essentially the same biological responses in vivo as naturally-occurring IL-8.
- Analog 12 (Sequence I.D. No. 12) was prepared in D-PBS.
- Analog 12 consists of 88.1% active peptide and the calculations were adjusted to compensate for the activity of Analog 12.
- Serial dilutions were then made resulting in solutions of appropriate doses of analog 12 in 0.2 ml.
- the animals were injected intraperitoneally with 0.2 ml of the appropriate solution 1 hour prior to arachidonic acid application.
- the study consisted of various dosage groups as well as excipient groups as contols.
- mice C57BL/6 females, which were obtained from Jackson Laboratories (age 8 weeks and weight 15-18g) .
- the mice were housed in conventional cages, fed pelleted food and given water ad libi tum.
- the arachidonic acid (Sigma Lot #42H7817) was dissolved in methyl alcohol resulting in a final concentration of 2 mg/20 ⁇ l. At time zero, 10 ⁇ l of arachidonic acid was applied to each side of the test ear using a pipettor. Each mouse received a total of 2 mg and a total volume of 20 ⁇ l. One hour post challenge, the test and control ears were measured for thickness using a Mitutoyo No. 7300 gauge caliper. The thickness was recorded in units of 0.001 inches. To determine the total edema, the measurement of the control ear was subtracted from the test ear measurement (arachidonic acid ear) .
- Analog 12 is an antagonist with in vivo bioactivity.
- the effect of Analog 12 on arachidonic acid-induced ear inflammation was evaluated in vivo .
- the application of arachidonic acid to the pinna of mice induces an immediate PMN-associated erythema and edema which may be measured by change in thickness.
- the administration of Analog 12 blocked edema with an approximate EC-50 of 1 ⁇ g/animal.
- NSAID phenidone
- Chemokines form a superfamily that is divided into two distinct functional classes: alpha and beta. All the members of each class share an organizing primary sequence motif. Alpha family members are distinguished by the C-X-C motif - where the first two cysteines of the motif are separated by an intervening residue. C-X-C chemokines are potent chemoattractants and activators for neutrophils. The beta family chemokines have a C-C motif and are equally potent chemoattractants and activators of monocytes. However, other roles are rapidly emerging for chemokines as well. Thus, both alpha and beta chemokines, have been shown to attract both memory T-cell and eosinophils as well as trigger the release of histamine from basophils. Edgington, discussed (Edgington et al. ,
- Receptor promiscuity presents one problem to drug design of the chemokines.
- individual receptors bind multiple ligands. Determining chemokine structure and function after dispensing with the dogma of "one ligand, one receptor" is extremely difficult, especially when target cells contain an ensemble of receptors on their membrane.
- chemokine receptors involved in binding the beta chemokines MCP-1, MlP-l ⁇ / 1 and RANTES. Based on studies to date, one receptor binds all three ligands, another binds only MIP- l / ⁇ and a third only binds MCP-1. Similar observations of receptor/1igand promiscuity are seen with the alpha chemokines.
- Type A receptors have a high affinity for IL-8 and low affinity for MGSA and NAP-2.
- the type B receptors bind IL-8 and MGSA with high and NAP-2 with intermediate affinity.
- DNA sequence data and X-ray diffraction data will facilitate rational drug design. Based on this knowledge, efficacious peptide analogs can be synthesized and assayed in the assays specified herein.
- Platelet factor 4 is carried within the alpha granules of platelets in the form of a non-covalent complex.
- PF-4 is a tetramer of four identical polypeptide chains, each of which contains 70 residues in the human moieties.
- white blood cells i.e., neutrophils and monocytes and it's release may be a signal that is involved in inflammation.
- Other possible functions of PF-4 derive from a strong binding to negatively charged polysaccharides especially heparan and heparin for which it has a dissociation constant of 10 "7-5 .
- the ability of PF-4 to neutralize heparin and related polymers is of general interest because heparin has been shown to interact with over 50 different enzymes to suppress muscle growth and to accelerate angiogenesis in solid tumors.
- PF-4 has recently been patented as
- Oncostatin A for its ability to inhibit tumor growth. It has also been shown to reverse immunosuppression in mice.
- PF-4 also binds tightly and preferentially to double stranded DNA in vi tro. This binding probably does not occur in vivo but it might be an important attribute of several recently discovered growth related proteins which are homologous to PF-4.
- Members of this class are 1) induced by IFN- ⁇ , 2) constitutively overexpressed in Chinese hamster and human cell lines, 3) strongly induced by Rous sarcoma virus and fibroblast cells and 4) over expressed in stimulated leukocytes.
- PF-4 does not induce comparable neutrophil responses although chemotaxis and exocytosis have been reported with concentrations that were 1,000 to 10,000- fold higher than those required for IL-8.
- PF-4 crystallizes as a tetramer, although the monomer structure is similar to that of IL-8.
- human PF-4 is in equilibrium among monomers, dimers, and tetramers.
- PF-4 and IL-8 share 35% sequence identity, including the four cysteines.
- Molecular modeling studies suggest that a similar folding pattern will be found for all members of the C-X-C family. Even MCP which belongs to the C-C family (beta chemokine) , has been found to have the same tertiary structure. Thus, it will be possible to sequence an agonist for PF4 in accordance with the present invention.
- Platelet basic protein is a highly specific platelet alpha granular protein that is a precursor of low affinity platelet factor 4 (LA-PF4) and beta thromboglobulin (3TG) . These proteins differ only in amino terminal amino acid sequence and isoelectric point. PBP is synthesized by megakaryocytes, contains 94 amino acids and is converted to LA-PF4 which contains 85 amino acid residues within megakaryocyte and platelet granules. jSTG itself (81 amino acid residues) as originally described cannot be detected in cell lysates prepared using trichloroacetic acid. It probably results from amino terminal cleavage of LA-PF4 or PBP after cell secretion.
- LA-PF4 low affinity platelet factor 4
- 3TG beta thromboglobulin
- LA-PF4 also referred to as connective tissue activating peptide III (CTAP-III)] is a weak mitogen for connective tissue fibroblasts. It has also been reported that 3TG antigen promotes chemotaxis in fibroblasts.
- NAP-2 neutrophil activating peptide
- NAP-2 is a 78 amino acid peptide corresponding to the major carboxy-terminal fragment of 0TG. It has 46% homology with NAP-l/IL-8. NAP-2 behaves as a typical chemotactic receptor agonist, inducing cytosolic free Ca + changes, chemotaxis, and exocytosis while PBB, LA-PF4 and PF4 have little such activity. It should be noted, as discussed above, that NAP-2 also interacts with the NAP-l/IL-8 receptors. Thus, in accordance with the present invention, it should be possible to synthesize agonists for NAP-2, including those that bind to the IL-8 beta receptor. EXAMPLE VIII
- IP-10 was originally isolated as a predominant messenger RNA form induced by IFN- ⁇ or LPS in monocytes and its expression has been detected in vivo during the development of a delayed type hypersensitivity cellular immune response by monocytes, endothelial cells, and infiltrating mononuclear cells. In addition, IP-10 expression has been seen in the epidermis, dermis and cutaneous lesions of psoriasis, tuberculoid leprosy, and fixed drug eruptions.
- IP-10 is a member of the chemokine superfamily and is approximately 30% homologous to IL-8 and PF-4. Recent studies have shown that IP-10 can elicit an anti- tumor inflammatory response that is capable of inhibiting the growth of plasmacytoma and mammary adenocarcinoma in immunocompetent mice. This effect is thymus dependent suggesting that IP-10 might act on T-cells. In addition, a neutrophil, and monocytic accumulation is seen as a result of IP-10 expression in immunocompetent but not nude mice. IP-10 does not have an ELR motif. ELR incorporation into IP-10 is not sufficient for IL-8 receptor interaction or neutrophil activation and suggests that IP-10 has a different receptor ligand conformation. However, hybrids formed between IL-8 and IP-10 could be designed which demonstrate that essential receptor binding motifs from the IL-8 sequence could be structured within the IP-10 molecule allowing IL-8 binding.
- IP-10 is expressed by activated but not by resting T-hybridoma cells, normal T-cells and thymocytes. While resting lymphocytes did not synthesize IP-10, a high level of IP- 10 transcripts are found in lymphoid organs (spleen, thymus, and lymph nodes) . Thymic and splenic stromal cells constitutively express high levels of both IP-10 messenger RNA and protein accounting for the high level of spontaneous expression in lymphoid tissue. Therefore, in addition to its role as a pro-inflammatory cytokine, IP-10 may participate in T-cell effector function of perhaps T-cell development. IP-10 expression has also been shown to be induced in delayed type contact hypersensitivity in sensitized animals. Thus, in accordance with present invention, we will be able to synthesize agonists for IP-10.
- GRO-ot which is also termed "melanoma growth stimulatory" activity.
- GRO- ⁇ r is expressed in human colon tumors along with GRO-3 and GRO-7.
- GRO- * and GRO-7 show 90 and 86% sequence homology with GRO- ⁇ .
- the GRO- ⁇ /MGSA alpha chemokine has potent chemotactic, growth regulatory and transformative functions.
- the function of GR0-3 and GRO-7 is unknown.
- GRO- ⁇ messenger RNA is selectively overexpressed in psoriasic epidermis and is reduced by therapy with Cyclosporin-A. It has been suggested that this over expression is a karyotinocyte response to activated T-cells in psoriasis.
- GRO- ⁇ /MGSA has been localized in a variety of cutaneous lesions. A raised level of immunoreactive GRO- ⁇ MGSA in diseased epidermis is detected in verruca vulgaris followed by psoriasis, keratoacanthoma, and squamous cell carcinoma. Detection of GRO-ot in basal cell carcinoma is variably present in the sclerosis variant and absent in the more common nodular variant.
- ENA-78 epidermal cell derived neutrophil activator
- ENA-78 shows significant amino acid sequence homology with NAP-2 (53%) , GRO- ⁇ (52%) , and IL-8 (22%) .
- ENA-78 appears to activate neutrophils through the IL-8 receptor.
- ENA-78 has been cloned in pigs and was initially described as alveolar macrophage derived chemotactic factor 2. It shares 53% sequence homology with human NAP-2 and 61% sequence homology with the GRO-related proteins. It also has 67% sequence homology with the 78 amino acid ENA-78 and is felt to represent the porcine variant thereof.
- ENA-78 was initially identified in the conditioned medium of stimulated human epithelial cell line A549. It is produced in response to stimulation with either IL-13 or TNF- ⁇ and is produced and secreted concomitantly with IL- 8, GRO- ⁇ , and GRO-7.
- ENA-78 consists of 78 amino acids and has a molecular weight of 8357. The four cysteines are positioned identically to those of IL-8 and similar analogues.
- ENA-78 stimulates neutrophils, induces chemotaxis, a rise in intracellular-free Ca + and exocytosis. Cross desensitization experiments indicate that ENA-78 acts through the same type of receptors as IL-8, NAP-2 and GRO- ⁇ .
- Recombinant human IL-8 was obtained from Bachem and radioiodinated with IODOGEN, (Pierce, IL) . Following purification by column chromatography, the radioligand was used in competitive binding assays using non- radiolabeled peptide analogs of the present invention. Analogs with the following sequences were synthesized and used as competitors. Parallel competitive binding studies were performed with the same analogs using another radiolabeled chemokine, Gro- ⁇ . The analogs used for this Example include Analogs 12 and 23-25, Sequence I.D. Nos. 12, 23, 24, 25) and were synthesized according to procedures set forth in Example 1.
- Analog 12 (Sequence I.D. No. 12) : Derived from IL-8 (this analog is sometimes referred to as "XXR")
- Analog 23 (Sequence I.D. No. 23): Derived from IL-8 (this analog is sometimes referred to herein as "CVC")
- Analog 25 (Sequence I.D. No. 25): Derived from IL-8 (this analog is sometimes referred to as "FH")
- the agonistic peptide analogs of the invention can act as immunostimulants in a manner similar to naturally occurring alpha chemokines, and may be useful as a protective agent for the immune system during chemotherapy and radiation therapy. Experiments were performed to determine if treatment of animals with Analog 1 could confer protection from myelosuppressive doses of gamma irradiation.
- mice C57BL/6 females, which were obtained from Jackson Laboratories (age 8 weeks and weight 15-18g) .
- the mice were housed in conventional cages, fed pelleted food and given water ad libitum.
- mice were administered Analog 1 continuously at a rate of 1 ⁇ l/mouse over a 24- hour period. During that time they were administered a dosage of 700 rads of gamma radiation from a cobalt source. Mice that received the Analog 1 treatment exhibited accelerated myeloid restoration following irradiation, as compared to mice that received a treatment of excipient only.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Polypeptide analogs derived from Interleukin-8 are provided. In one embodiment, these reagents act as agonists of alpha chemokines and are useful as chemotherapeutic compounds for the treatment of neoplasms, including solid tumors and leukemias. They may also be efficacious in the treatment of infectious diseases mediated by microorganisms, such as bacteria, fungi and viruses. In another embodiment, these peptides analogs have antagonist activity for alpha chemokines and therefore may be used as anti-inflammatory agents, as well as in the treatment of autoimmune disease and various chronic inflammatory conditions such as rheumatoid arthritis and psoriasis.
Description
POLYPEPTIDE AGONISTS AND ANTAGONISTS OF HUMAN INTERLEUKIN-8
FIELD OF THE INVENTION
The present invention relates to polypeptide analogs of the human cytokine interleukin 8 that function as agonists or antagonists of interleukin 8 and other human alpha chemokines. The invention also provides methods of using these peptide analogs to augment or inhibit various biological responses associated with alpha chemokines.
BACKGROUND OF THE INVENTION Interleukin 8 (IL-8) is a human cytokine that promotes the recruitment and activation of neutrophil leukocytes and represents one of several endogenous mediators of the acute inflammatory response. In the past it was variously termed neutrophil-activating factor, monocyte-derived neutrophil chemotactic factor, interleukin-8 (IL-8) , and neutrophil-activating peptide- 1, (NAP-1) . The term IL-8 has gained the widest acceptance and will be used herein.
The most abundant naturally occurring form of the IL-8 monomer is a 72-residue protein apparently derived by processing of a 99-residue precursor. Other proteins with related sequences, including neutrophil- activating peptide-2 and GROCK (with melanoma growth stimulatory activity) , are IL-8 homologues which have neutrophil-activating properties.
IL-8 is a member of the chemokine superfamily that is divided into two distinct functional classes: alpha (o.) and beta (3) . The members of each class share an organizing primary sequence motif. The a members are distinguished by a C-X-C motif with the first two cysteines in the motif separated by an intervening residue. C-X-C chemokines are potent chemoattractants and activators for neutrophils, and are represented by IL-8. The jS family chemokines have a C-C motif and are
equally potent chemoattractants and activators of monocytes. It appears that the two sides of the chemokine family have clearly defined functions: the C- X-C subfamilies cannot activate monocytes while the C-C subfamily has no effect on neutrophils. Although these two families of chemokines have similar three dimensional structures, they demonstrate fairly low sequence homology (30 to 35%) . Proteins within the same family, such as platelet factor four (PP-4) , are structurally related to IL-8 (35% sequence identity) but lack the N terminal ELR sequence (Glu-Leu-Arg) which has been shown by site directed mutagenesis to be critical for IL-8 activity. Thus, PF-4 has an entirely different profile of biological activity. Indeed, when the ELR sequence is added to the N-terminus of PF-4 it has been found that the modified protein has potent neutrophil activation and chemoattractant properties (Clark-Lewis et al., Biochemistry .90.-3574-3577, 1993) . However, this is not true for all of the chemokines since two of the proteins related to IL-8, interferon inducible protein (IP-10) and monocyte chemoattractant protein 1 (MCP-1) do not acquire neutrophil activating properties when the ELR structural determinants are added. Interestingly, when the E and the L of the ELR motif are removed from IL-8 the molecule acts as an antagonist for IL-8 (Moser, B., et al., J. Biol. Chem. 168.:7125-7128, 1993) .
In other studies by Clark-Lewis (Clark-Lewis, I., et al., J. Biol. Chem. 269:16075-16081. 1994) it was shown that conservative substitutions are accepted into the 10-22 region of IL-8, which is not the case for the ELR motif (residues 4-6) . These investigators observed that the disulfide bridges and the 30-35 turn provide a structural scaffold for the NH-2 terminal region which includes a primary receptor binding site (ELR motif) and secondary binding and conformational determinants similar to those seen in residues 10 through 22. Other studies using mutants of IL-8 and melanoma growth stimulating
activity (MGSA) and recombinant IL-8 ot/β receptors stably expressed in human cells demonstrated that there was a second site on the molecule responsible for binding. It appears that the carboxy terminus distal to amino acid 50 is not important in high affinity binding to the c. receptor although both the amino and carboxy termini appear to be important for binding to the β receptor (Schraufstatter, I.S., et al., J. Immunol. 151:6418-6428, 1993) . In summary, it appears that IL-8 posesses at least two and maybe three regions responsible for binding of IL-8 to its receptor. Further, the specific contact pharmacophore may vary depending upon whether or not the c. or the β receptor is being examined.
Inflammation and autoimmune responses are initiated by leukocytes which migrate out of the microvasculature and into the extravascular space in response to chemoattractant molecules. These chemoattractants may be released from the host and include cytokines and activated complement components. Alternatively, they may be released from an invading organism (e.g., N-formylated peptides or MDP dipeptide) . Once exposed to chemoattractants within the vasculature, the leukocytes become activated and capable of adhering to the endothelium, providing the first step in the development of inflammation. Stimulated neutrophils adhere to the endothelium of the microvasculature in response to a gradient of chemoattractants which direct the cells into the extravascular space toward the source of the chemoattractant. (Anderson et al. , J. Clin. Invest. 74.:536-551, 1984; Ley, K. , et al. , Blood 77:2553- 2555, 1991; Paulson, J.C., Selectin/carbohydrate-mediated adhesion of leukocytes, Adhesion: Its Role in Inflammatory Disease, W. H. Freeman, 1992; Lasky, L.A., The homing receptor (LECAM 1/L-selectin) , Adhesion: Its role in inflammatory disease, W. H. Freeman, 1992.)
Bevilacqua (Bevilacqua et al., J. Clin. Invest. 7_6.:2003-2011, 1985) has demonstrated that cytokine and
6/09062 PCIYUS95/12099
- 4 - endotoxin release stimulates the endothelium to become more adhesive for leukocytes. Subsequent observations (Buyon, J.P., et al., Clin. Immunol. Immunopathol. 46.:141-149, 1988; Abramson, S.B., et al. , Hosp. Pract. 23.:45-56, 1988; Clark-Lewis, I. et al. , supra. 1993); have suggested that the endothelium has a critical role in the events leading to the development of the inflammatory lesion. This model of inflammation suggests that leukocytes are directed to an inflamed locus by stimulated endothelium. After stimulation with cytokines or bacterial products, the endothelium arrests leukocytes as they traverse (roll along) the microvasculature near sites of inflammation. After being forced to stop in the microvasculature, the leukocytes are then activated to adhere more tightly to the endothelium and to migrate to the abluminal aspect of the vessel. The leukocyte, once it is out of the blood vessel, is then capable of following a gradient of chemoattractants toward the exciting pathogen. Vascular endothelium, activated by stimulants such as IL-1, IL-8, TNF, or LPS, appears to play a pivotal role in this process through the production of pro-inflammatory substances, including chemoattractants and cytokines such as chemokines. The inflammatory properties of IL-8 were initially demonstrated from a purified natural product injected intradermally into rabbits (Rampart, M. et al. , Am. J. Path. 125. (1) :21-25, 1989) . More recently, neutralizing antibodies to human IL-8 were shown to have a protective effect in inflammatory lung injury in rats. This antibody blocked the glycogen-induced accumulation of neutrophils in rats and was protective against lung interdermal vascular injury induced by the disposition of IgG immune complexes. This latter model of injury has been shown to be E-selectin dependent. The protective effect of the neutralizing antibody correlated with reduced tissue accumulation of neutrophils as measured by
myeloperoxidase conten . Preliminary nonhuman primate studies have confirmed the activity of IL-8 on hematological parameters. IL-8 was administered by both bolus and continuous infusion to baboons. This resulted in a rapid, transient and severe granulocytopenia followed by granulocytosis that persisted as IL-8 levels remained detectable within the circulation. Histopathological examination revealed a mild to moderate neutrophil margination in the lung, liver and spleen which was of greater severity in animals receiving the continuous infusion of IL-8.
High levels of intravascular IL-8 have been reported in systemic conditions such as septic shock (Danner, R.L., et al., Clin. Res. 3J3-352A, 1990) . These authors have speculated that intervascular IL-8 may impair leukocyte adhesion and thus protect organs from PMN mediated injury. The intravenous administration of IL-8 induced an immediate and transient neutropenia that was similar in kinetic profile to that described with other chemoattractants. This neutropenia was a result of pulmonary PMN sequestration and is consistent with the demonstration of abundant IL-8 receptor on PMNs. Following this transient neutropenia, (approximately 30 minutes) cells recirculate with a normal half life. Shortly thereafter neutrophilia, a characteristic of IL- 8, is observed. The neutrophilia likely reflects recruitment of mature PMNs to a marginal pool in the lung and other organs as well as immature PMNs from the marrow. Endothelial cells can exert both proinflammatory and anti-inflammatory effects by virtue of the mediators they generate. Endothelial cells can be stimulated to generate IL-8, but unlike other mediators, IL-8 may be released from the endothelial cell. Alternatively, endothelial cell produced IL-8 is an important chemoattractant and activator of neutrophils . There is evidence that systemic IL-8 can bind to
endothelial cells, causing a local activation of the endothelium that results in the ability of this altered endothelium to attract neutrophils that have come into contact with the (activated) endothelium. One working hypothesis is that IL-8 initially functions as a proinflammatory cytokine, whereas its continued generation and release from the endothelium ultimately causes a down regulation of neutrophils, with a curtailment in their further recruitment. Whether the cell associated IL-8 or released IL-8 provides the vital contribution to the outcome of the inflammatory response remains unresolved.
IL-8 receptors are "promiscuous" and respond with a calcium flux when bound by structurally related ligands with the following order of potency: IL-8 > MGSA > NAP-2. The order of potency correlates with the effectiveness of these compounds in binding to neutrophils during competitive binding assays with the radio-labeled IL-8. C5a, a structurally related chemoattractant that is similar in size and charge to IL- 8 and which has a receptor in the same family, does not activate the IL-8 receptor.
The in vi tro effects of IL-8 on neutrophils are similar to those of other chemotactic agonists such as C5a and fMet-Leu-Phe and include induction of a transient rise in cytosolic free calcium, the release of granules containing degradative enzymes such as elastase, the respiratory H202 burst, neutrophil shape change, and chemotaxis. IL-8 appears to bind to at least one class of receptor sites on neutrophils with a frequency of approximately 64,000/cell and a K<, of 0.2 nM.
The three-dimensional structure of IL-8 is known by two-dimensional NMR and x-ray diffraction techniques. The IL-8 monomer has antiparallel β strands followed by a single overlying COOH-terminal α; helix. Two disulfide bridges, between cysteines 7 and 34, and between cysteines 9 and 50 seem to stabilize the tertiary
structure. Residues 1-6 and the loop residues 7-18 seem to have little defined secondary structure. In solution, IL-8 is a noncovalent homodimer which is stabilized primarily by interactions between the β strands of the two monomers.
Examination of the three-dimensional structure indicates that following the cysteine at position 50, the residues form a type iβ turn (at residues 51 to 55) followed by an amphipathic a helix (at residues 55 to 72) that transverses the β sheet. The hydrophobic face of the c. helix interacts with and stabilizes the hydrophobic face of the β sheet. Some of the interactions are between the two subunits of the dimeric molecule.
Interleukin-8 has shown both anti-tumor and anti-infective therapeutic activity. IL-8 has been shown to induce the regression of macroscopic tumors in a model of peritoneal carcinomatosis in the rat. In this model, IL-8 was shown to recruit PMN to the challenge site but did not enhance PMN infiltration of the tumor or the cytotoxic activity of PMN. Regardless, it did have significant therapeutic activity which may be secondary to PMN cytotoxicity and associated with other intermediate cells. It is suggested that lymphocytes could be involved since IL-8 has also demonstrated the ability to stimulate T-cell chemotaxis. (Lejeune, P., et al. , Cancer Immunol. Immunotherapy. 3.8:167-170, 1994). Similarly, Interleukin-8 has shown therapeutic activity in nonneutropenic mice who received IL-8 shortly before challenge and at the site of infectious challenge with either P. aeruginosa, Klebsiella -pneumoniae, or
Pi asmodi urn -berghei . (Vogels, M.T., et al. , Antimicrob- Agents-Chemother. 3_7:276-280, 1993) .
In other antitumor studies IP-10, an alpha chemokine whose secretion is induced by IFN-γ and LPS, was genetically engineered into tumor cells. The expression of IP-10 by several tumor cell lines had no effect on the growth of these tumor cells in vi tro but
elicited a powerful host mediated anti-tumor effect in vivo. Indeed, tumors genetically engineered to secrete IP-10 elicited a T-lymphocyte dependent anti-tumor response resulting in the rejection of tumors in vivo. Animals injected with these tumor cells do not develop tumors or develop tumors which spontaneously regress. Furthermore, administration of parental tumor cells admixed with IP-10 secreting tumor cells do not give rise to tumors in experimental animals. This suggests that in addition to being chemotactic for T-cells (Clark- Lewis, I., et al., supra, 1994) alpha chemokines may also act as T-cell adjuvants and therapeutics via T-cell chemotaxis and/or augmentation (Luster, A.D., J..Exp. Med. 178.:1057-1064, 1993). Because of its demonstrated anti-tumor and anti-infective activities, considerable interest exists in developing specific IL-8 agonists as immune adjuvants and anti-tumor agents for treatment of immunocompromised patients or patients with various forms of cancer. One strategy for developing agonists is to prepare polypeptide analogs which correspond to the known or suspected binding domains of naturally occurring IL-8 and related alpha chemokines. Such analogs are often found capable not only of binding to a cognate receptor, but of stimulating a desired biological response, such as anti- tumor activity for IL-8.
As it is established that IL-8 is also a key mediator of inflammatory diseases, it would also be desirable to identify substances capable of blocking or interrupting the activity of IL-8 for use in anti- inflammatory compositions. Such compositions may prove to be advantageous over presently available NSAID's, steroid based anti-inflammatory drugs and cytotoxic drugs which often have severe side-effects with the continued usage that is required for chronic inflammatory diseases. It would also be desirable to identify IL-8 analogs
having an increased inflammatory activity for medical research applications.
IL-8 has been previously produced through chemical synthesis (Clark-Lewis, et al. , Biochemistry 30: 3128-3135, 1991) and by recombinant DNA methods (Herbert, et al., J. Biol. Chem. 286: 18989-18994, 1991). In addition, it is known that IL-8 exists in several forms that vary at the NH2 -terminus, which have been detected in preparations purified from natural sources. These variations correspond to the predominant 72-residue form (which is generally considered to be the prototype IL-8 molecule) ; a 77-residue form having 5 additional NH2 - terminus amino acids on each monomer; and, two shortened forms having residues 3-72 and 4-72 of the 72 amino acid form, respectively.
SUMMARY OF THE INVENTION
The present invention involves low molecular weight peptides which have agonistic or antagonistic activity for IL-8 or other alpha chemokines. The peptide agonists have an amino acid sequence with the following formula:
Glu-Leu-Arg-Cys-Xaa1-Cys-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7- Xaag-Xaa9-XaajQ-Xaajj-Xaaj2 wherein
Xaa2 is lie, or Val; Xaa3 is Lys, Gin, or Ser; Xaa4 is Thr, or lie; Xaa5 is Tyr, Leu, Met, His, Val, or Thr; Xaa6 is Ser, Gin, Thr, or Ala; Xaa7 is Lys, Arg, or His; Xaa8 is absent or is Pro, Phe, or Gly; Xaa9 is absent or is Phe, lie, or Val; Xaa10 is absent or is His, Lys, or Arg;
Xaaπ is absent or is Pro, Leu, or Phe; and
Xaa12 is absent or is Lys, His or Arg.
More particularly, a preferred embodiment of the present invention comprises an amino acid sequence with agonist activity substantially equivalent to Glu- Leu-Arg-Cys-Gln-Cys-Ile-Lys-Thr-Tyr-Ser-Lys-Pro-Phe-His- Pro-Lys as well as similar analogs having additional N- terminal amino acids. These polypeptides act as anti- cancer and anti-infective agents for the therapy of leukemia and solid tumors and metastatic disease. These embodiments also have anti-infective therapeutic activity for viral, bacterial, fungal, yeast and parasitic infections.
In other embodiments of the invention, the polypeptide is modified selectively to provide additional agonists of IL-8. In one particular embodiment, IL-8 agonists may include peptides truncated by 3 amino acid residues at the C terminus by deletion. In another particular embodiment, agonists for IL-8 or other alpha chemokines include cysteine substitutions by aminobutyric acid, homocysteine or diaminosuberic acid.
The inventor herein has investigated several low molecular weight peptide analogs of IL-8 with biological activity that substantially compete for IL-8 binding and are based on IL-8 sequences. Truncation of native IL-8, particularly in the C-terminal region thereof, yields IL-8 peptidal mimetics having the therapeutically useful properties of anti-neoplastic and anti-infective drugs. More particularly, the IL-8 low molecular weight peptide analogs of the present invention comprise an amino acid sequence with biological activity substantially equivalent to the IL-8 sequence beginning at residue 4 and continuing through residue 20, wherein at least the N-terminal residues found to be critical for neutrophil binding and stimulation, i.e., Glu-4, Leu-5, Arg-6 are contained at the N-terminal region.
In a further embodiment, IL-8 analogs include an additional two or three residues at the amino terminus of the 20 residue peptide so as to provide the 1-20 forms that are also useful as IL-8 agonists. In addition, significant biological activity is associated with low molecular weight peptide analogs from residue 4-17. The resulting in a 13 amino acid peptide also has agonist activity for IL-8.
Accordingly, this invention provides a biologically active human IL-8 low molecular weight peptide analog having an amino acid sequence substantially equivalent to the IL-8 polypeptide, beginning at residue 4 and continuing to residue 17 or 20. In an alternative embodiment of the present invention, IL-8 peptide analogs with antagonistic activity have also been synthesized. These peptide analogs are comprised of an amino acid sequence substantially equivalent to those described above, except lacking the N-terminal pair of residues (i.e., Glu-Leu) . The antagonist analogs compete strongly with IL-8 for neutrophil binding without signal transduction, due to the deletion of Glu-Leu (two-thirds of the "ELR" motif required for signal transduction activity) . In preferred embodiments, the peptide comprises the sequence: Arg-Cys-Gln-Cys-Ile-Lys-Thr-Tyr-Ser-Lys- Pro-Phe-His-Pro-Lys as well as similar analogs having either one or two additional N-terminal amino acids. In another particular embodiment, antagonists that compete with IL-8 yet still retain antagonist properties are obtained by replacing residues Glu and Leu with non-polar amino acids, such as Ala, Val or Leu.
In other embodiments of the invention, the IL-8 sequence is truncated from residue 21 to the C-terminus as well at N-terminal residues 1 to 5. Thus the antagonist analogs which contain the N-terminal residues found to be critical for neutrophil binding and
stimulation, i.e., Arg 6, begin at residue 6 and continue through residue 20.
IL-8 analogs have also been synthesized that include an additional one or two non-polar residues at the amino terminus of the 14 residue peptide so as to provide the 4 or 5-20 forms that are also useful as IL-8 antagonists. In addition, significant biological activity is associated with low molecular weight peptide analog from residue 6-17 resulting in a 12 amino acid peptide with antagonist activity for IL-8.
Accordingly, this invention also provides a human interleukin-8 low molecular weight peptide analog with antagonist activity having an amino acid sequence substantially equivalent to those found at the N-termini of native IL-8, i.e., amino acids 6 through 20 or 6 through 17. Further, equal or greater activity is associated with the addition of Ala, Val, Leu or other amino acid at residue 4 and 5.
This invention also provides methods of use of these agonistic and antagonistic peptide analogs of human IL-8 both in vivo and in vi tro.
In contrast to the claimed invention in PCT/CA92/00528 (W0 93/11159) which describes a 77 amino acid antagonist to IL-8, the embodiments of the present invention are related to low molecular weight peptide analogs of IL-8 which are less than 30, more preferably less than 20, and most preferably 11 to 17 amino acids in length. This shorter length allows for more rapid and extensive tissue distribution of the drug on administration as compared to a 70 amino acid therapeutic. Further, this invention substantially increases the purity of the product through reduced errors inherent to the manufacture of a large protein. In addition, this invention has a significant reduction in the cost of goods as compared to the invention in the aforementioned patent. Based on the homogeneity of the alpha chemokines, both sequence and three dimensional,
agonists and antagonists for both known and additional alpha chemokines can be derived based on the present invention. The present claims include information on the reduction to practice of an invention specific for the IL-8 ligand and receptor.
BRIEF DESCRIPTIONS OF THE DRAWINGS
Figure 1: FACS analysis profiles of Ca+ release from polymorphonuclear monocytes (PMNs) , unstimulated (Fig. 1A) or stimulated with native IL-8 (Fig. IB) .
Figure 2: FACS analysis profiles of Ca+ release from untreated (Fig. 2A) and PBS treated (Fig. 2B) PMNs.
Figure 3: FACS analysis profiles of Ca+ release from untreated (Fig. 3A) and analog 1 treated PMNs (Fig. 3B) .
Figure : FACS analysis profiles of Ca+ release from untreated PMNs (Fig. 4A) and PMNs treated with IL-8 and analog 12.
Figure 5: A graph of a dose response curve showing the chemotactic effects of a single i.p. injection of analog 1 in increasing concentrations. X axis represents the dose of analog 1 in μg/animal; Y axis depicts cell number x 106 in the peritoneum.
Figure 6: A graph of a dose response curve showing the chemotactic effects of a single i.p. injection of analog 1 in increasing concentrations. X axis represents the dose of analog 1 in μg/animal; Y axis depicts cell number x 106 in the peripheral blood.
Figure 7: A graph showing the different cell types present in the peritoneum in response to increasing amounts of i.p. injected analog 1. The X axis represents the dose of analog 1 in μg/animal; The Y axis represents cell number x 106 in the peritoneum. • lymphocytes;
■ PMNs; A monocytes.
Figure 8 : A graph showing the absolute cell number of different cell types present in the peritoneum after an i.p. injection of analog 1. The X axis represents the dose of analog 1 in μg/animal; The Y axis represents cell number x 106 in the peritoneum. • lymphocytes; ■ PMNs; A monocytes.
Figure 9 : A graph showing the different cell types present in the peripheral blood after a single i.p. injection of analog 1. The X axis represents the dose of analog 1 in μg/animal . The ratio of lymphocytes to PMNs is shown on axis Yl; the number of monocytes is shown on Y2. • lymphocytes; ■ PMNs; A monocytes.
Figure 10 : A graph showing the absolute cell number of different cell types present in the peripheral blood after a single i.p. injection of analog 1. The X axis represents the dose of analog 1 in μg/animal. The ratio of lymphocytes to PMNs is shown on axis Yl; the number of monocytes is shown on Y2. • lymphocytes; ■ PMNs; A monocytes.
Figure 11: A graph showing the kinetics of the in vivo chemotactic response in the peritoneum following an i.p. injection of 10 μg of analog 1. The X axis represents time in hours and the Y axis represents the
absolute cell number. • lymphocytes; ■ PMNs; A monocytes.
Figure 12 : A graph showing the effects of increasing doses of analog 12 on arachidonic acid induced ear inflammation in mice. The X axis represents increasing doses of analog 12 in μg/animal . The Y axis represents ear thickness measured in units of .001 inches .
Figure 13 : Graphs of competitive binding assays showing the ability of peptide analogs to displace radiolabled IL-8 from the IL-8 receptor. The X axis represents increasing molar amounts of analog. The Y axis shows the % of total binding. The analogs tested are as follows: 13A XXR, Sequence I.D. No. 12; 13B CVC, Sequence I.D. No. 23; 13C CMC, Sequence I.D. No. 24; 13D FH, Sequence I.D. No. 25.
Figure 14: Graphs of competitive binding assays showing the ability of peptide analogs to displace radiolabled Groα from the IL-8 receptor. The X axis represents increasing molar amounts of analog. The Y axis shows the % of total binding. The analogs tested are as follows: 13A XXR, Sequence I.D. No. 12; 13B CVC, Sequence I.D. No. 23; 13C CMC, Sequence I.D. No. 24; 13D FH, Sequence I.D. No. 25.
DETAILED DESCRIPTION OF THE INVENTION In order to provide an understanding of several of the terms used in the specification and claims, the following definitions are provided:
Biological activity - The term biological activity is a function or set of functions performed by a molecule in a biological context (i.e., in an organism or an in vi tro surrogate or facsimile model) . For IL-8 or other alpha chemokines, biological activity is
characterized by chemotactic activity (preferably PMNs but may also include T lymphocytes and/or monocytes/macrophages) . It may also include second messenger and/or increases in elastase activity by PMNs. A low molecular weight peptide analog - This identifies a natural or mutant (mutated) analog of a protein (generally less then 20-30 residues in length, comprising a linear or discontinuous series of fragments of that protein which may have one or more amino acids replaced with other amino acids and which has altered, enhanced or diminished biological activity when compared with the parent or non-mutated protein.
Substantially equivalent biological activity - is that profile of activity which defines IL-8 or other alpha chemokines. In in vitro surrogate models this may include chemotaxis of PMNs, T lymphocytes or monocytes; Ca++ signal transduction; or increases in elastase activity. In vivo this would be defined as the chemotaxis of PMNs to a localized site for example the peritoneum following i.p. injection or to the peripheral blood.
Substantially or essentially equivalent peptide analogs. An analog is essentially equivalent to another if it has one or more of the biological activities characteristic of human IL-8, essentially has the same number of amino acids as the analog specified in Tables 2 and 3 with no more than two additions or deletions and, in comparison with the sequence of the specified analog, has at most five amino acid substitutions, all of which would be considered neutral in the art (i.e., acidic for acidic, basic for basic, uncharged polar for uncharged polar, hydrophobic for hydrophobic, and the like) .
The present invention provides composition comprising short polypeptide analogs of IL-8 or related alpha chemokines that bind to cellular chemokine receptors and act as agonists or antagonists of IL-8 or other alpha chemokines. These polypeptide analogs
generally correspond to the amino-terminal domain of IL-8 or related chemokines, as described in greater detail herein. The complete amino acid sequence of naturally- occurring IL-8 has been published (Clark-Lewis et al., J. Biol. Chem. 269: 16075-16078, 1994); the twenty amino acid residues comprising the amino-terminal domain is set forth below as Sequence I.D. No. 26 (the N-terminal Ser is residue number 1; the C-terminal Lys is residue number 20) : Ser-Ala-Lys-Glu-Leu-Arg-Cys-Gln-Cys-Ile-Lys-Thr-Tyr-Ser- Lys-Pro-Phe-His-Pro-Lys.
It has been discovered in accordance with the present invention that short, amino-terminal peptide analogs of IL-8 and alpha chemokines are capable of binding to their cognate receptors and depending on the inclusion of the Glu-Leu-Arg ("ELR") domain at the amino terminus, can tranduce biological signals associated with native IL-8 and other alpha chemokines. Thus, peptide analogs of the present invention that contain the ELR domain can act as IL-8 agonists. It has also been discovered in accordance with the present invention that removal of the ELR domain from the peptides of the invention results in analogs capable of binding cognate receptors, but incapable of signal transduction. These analogs are useful as antagonists of IL-8 and other alpha chemokines. The overall sizes and structures of the analogs are similar except that the agonist group contains the intact ELR domain while the antagonist group is lacking most of the domain.
TABLE 1
The amino acids are identified in the present application according to the three-letter or one-letter abbreviations in the following Table 1:
3-letter 1-letter
Amino Acid Abbreviation Abbreviati on
L-Alanine Ala A
L-Arginine Arg R
L-Asparagine Asn N
L-Aspartic Acid Asp D
L-Cysteine Cys C
L-Glutamine Gin Q
L-Glutamic Acid Glu E
Glycine Gly G
L-Histidine His H
L-Isoleucine He I
L-Leucine Leu L
L-Methionine Met M
L-Norleucine NorLeu J
L-Ornithine Orn 0 -Phenylalanine Phe F
L-Proline Pro P
L-Serine Ser S
L-Threonine Thr T
L-Tryptophan Trp W
L-Tyrosine Tyr Y
L-Valinβ Val V
L-Lysine Lys K
"Asx" means Asp or Asn
"Glx" eans Glu or Gin
The present invention includes peptide sequences with agonist activity having the following formula:
Glu-Leu-Arg-Cys-Xaa1-Cys-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7- Xaag—Xaan—Xaa<n—Xaaii—Xaaι7 wherein
Xaa! is Gin, Met, or Val; Xaa2 is lie, or Val; Xaa3 is Lys, Gin, or Ser; Xaa4 is Thr, or lie;
Xaa5 is Tyr, Leu, Met, His, Val, or Thr; Xaa6 is Ser, Gin, Thr, or Ala; Xaa7 is Lys, Arg, or His; Xaa8 is absent or is Pro, Phe, or Gly; Xaa9 is absent or is Phe, He, or Val; Xaa10 is absent or is His, Lys, or Arg; Xaan is absent or is Pro, Leu, or Phe; and Xaa12 is absent or is Lys, His or Arg.
TABLE 2
Exemplary of the analogs of the present invention having agonist activity are the following:
Analog 1 (Sequence I.D. No. 1) :
Derived from Alpha Chemokine - IL-8 (also called NAP-1) Glu-Leu-Arg-<Zys-Gln-Cys-lie-Lys-Thr-Tyr-Ser-Lys-Pro-
Phe-His-Pro-Lys
Analog 2 (Sequence I.D. No. 2) :
Derived from Alpha Chemokine - IL-8 (also called NAP-1)
Glu-Leu-Arg-Cys-Gln-Cys-Ile-Lys-Thr-Tyr-Ser-Lys-Pro- Phe
Analog 3 (Sequence I.D. No. 3) :
Derived from Alpha Chemokine - GRO-α; (also called MGSA)
Glu-Leu-Arg-Cys-Gln-Cys-Leu-Gln-Thr-Leu-Gln-Gly-Ile-
His-Pro-Lys Analog 4 (Sequence I.D. No. 4) :
Derived from Alpha Chemokine - GR0-/S (also called MIP-2σ)
Glu-Leu-Arg-Cys-Gln-Cys-Leu-Gln-Thr-Leu-Gln-Gly- He- Hi s- Leu -Lys
Analog 5 (Sequence I.D. No. 5) : Derived from Alpha Chemokine - GRO Glu-Leu-Arg-Cys-Gln-Cys-Leu-Gln-Thr-Met-Thr-Gly-Val- His-Leu-Lys
Analog 6 (Sequence I.D. No. 6): Derived from Alpha Chemokine - GRO-7 (also called MIP-23)
Glu-Leu-Arg-Cys-Gln-Cys-Leu-Gln-Thr-Leu-Gln-Gly-His- Leu-Lys
Analog 7 (Sequence I.D. No. 7) :
Derived from Alpha Chemokine-3 thromboglobulin (also called NAP-2)
Glu-Leu-Arg-Cys-Met-Cys-Ile-Lys-Thr-Thr-Ser-Gly-Ile- His-Pro-Lys
Analog 8 (Sequence I.D. No. 8) : Derived from Alpha Chemokine - 9E3
Glu-Leu-Arg-Cys-Gln-Cys-He-Ser-Thr-His-Ser-Lys-Phe- Ile-His-Pro-Lys Analog 9 (Sequence I.D. No. 9) :
Derived from Alpha Chemokine - 310C
Glu-Leu -Arg- Cys -Gin- Cys- He -Lys -Thr- Tyr-Ser-Lys - Pro- Phe-His-Pro-His
Analog 10 (Sequence I.D. No. 10) : Derived from Alpha Chemokine - CNC
Glu-Leu-Arg-Cys-Gln-Cys-Leu-Gln-Thr-Val-Ala-Gly-He- His-Phe-Lys
Analog 11 (Sequence I.D. No. 11) : Derived from Alpha Chemokine - ENA-78 Glu-Leu-Arg-Cys-Val-Cys-Leu-Gln-Thr-Thr-Gln-Gly-Val- His-Pro-Lys
TABLE 3
Preferred embodiments of the peptides of the present invention with antagonist activity are presented in Table 3 which follows: Analog 12 (Sequence I.D. No. 12) :
Derived from Alpha Chemokine - IL-8 (also called NAP-1; this analog is sometimes referred to herein as "XXR")
Arg-Cys-Gln-Cys-He-Lys-Thr-Tyr-Ser-Lys-Pro-Phe-His- Pro-Lys Analog 13 (Sequence I.D. No. 13) :
Derived from Alpha Chemokine - IL-8 (also called NAP-1)
Arg-Cys-Gln-Cys-He-Lys-Thr-Tyr-Ser-Lys-Pro-Phe Analog 14 (Sequence I.D. No. 14) :
Derived from Alpha Chemokine - GRO a (also called MGSA) Arg-Cys-Gln-Cys-Leu-Gln-Thr-Leu-Gln-Gly-He-His-Pro- Lys
Analog 15 (Sequence I.D. No. 15) : Derived from Alpha Chemokine - GRO-3 (also called MIP-2α)
Arg-Cys-Gln-Cys-Leu-Gln-Thr-Leu-Gln-Gly-He-His-Leu- Lys
Analog 16 (Sequence I.D. No. 16): Derived from Alpha Chemokine - GRO
Arg-Cys-Gln-Cys-Leu-Gln-Thr-Met-Thr-Gly-Val-His-Leu- Lys Analog 17 (Sequence I.D. No. 17) :
Derived from Alpha Chemokine - GRO y (also called MIP-23)
Arg-Cys-Gin-Cys-Leu-Gin-Thr-Leu-Gin-Gly-His-Leu-Lys Analog 18 (Sequence I.D. No 18) :
Derived from Alpha Chemokine-B thromboglobulin (also called NAP-2)
Arg-Cys-Met-Cys-Ile-Lys-Thr-Thr-Ser-Gly-Ile-His-Pro- Lys
Analog 19 (Sequence I.D. No. 19) : Derived from Alpha Chemokine - 9E3 Arg-Cys-Gln-Cys-Ile-Ser-Thr-His-Ser-Lys-Phe-He-His- Pro-Lys
Analog 20 (Sequence I.D. No. 20): Derived from Alpha Chemokine - 310C
Arg-Cys-Gln-Cys-He-Lys-Thr-Tyr-Ser-Lys-Pro-Phe-His- Pro-His
Analog 21 (Sequence I.D. No. 21) : Derived from Alpha Chemokine - CNC
Arg-Cys-Gln-Cys-Leu-Gln-Thr-Val-Ala-Gly-He-His-Phe- Lys Analog 22 (Sequence I.D. No. 22) :
Derived from Alpha Chemokine - ENA-78 Arg-Cys-Val-Cys-Leu-Gln-Thr-Thr-Gln-Gly-Val-His-Pro- Lys
Analog 23 (Sequence I.D. No. 23) :
Derived from IL-8 (this analog is sometimes referred to herein as "CVC")
Arg-Cys-Val-Cys-lie-Lys-Thr-Tyr-Ser- ys-Pro-Phe-His- Pro-Lys
Analog 24 (Sequence I.D. No. 24) :
Derived from 11-8 (this analog is sometimes referred to herein as "CMC")
Arg-Cys-Met-Cys-He-Lys-Thr-Tyr-Ser-Lys-Pro-Phe-His- Pro-Lys Analog 25 (Sequence I.D. No. 25):
Derived from IL-8 (this analog is sometimes referred to as "FH")
Arg-Cys-Gln-Cys-Ile-Lys-Thr-Tyr-Ser-Lys-Pro-Phe-His
The present invention includes analogs that are essentially equivalent to any analog of the invention, as specified in Tables 2 and 3. As defined above, an analog is essentially equivalent to one specified above if it has one or more of the biological activities characteristic of human IL-8, essentially has the same number of amino acids as the analog specified in Tables 2 and 3 with no more than two additions or deletions and, in comparison with the sequence of the specified analog, has at most five amino acid substitutions, all of which would be considered neutral in the art (i.e., acidic for acidic, basic for basic, uncharged polar for uncharged polar, hydrophobic for hydrophobic, and the like) . The acidic amino acids are Asp, Glu and gammacarboxyglutamic acid. The basic amino acids are
Arg, Lys, His and Orn. The hydrophobic amino acids are Ala He, Leu, Met, Nor, Phe, Trp, Tyr, Val, t- butylglycine, norvaline, cyclohexylalanine, t- butylalanine, amino-4phenybutyric acid, beta-2-thienylala nine, p-bromophenylalanine, p-chlorophenylalanine, p- iodophenylalanine, p-nitrophenylalanine, 3.5- diiodotyrosine, phenylglycine, and napthylalanine. Uncharged polar amino acids are Asn, Gin, Ser, and Thr. Gly can be substituted for an uncharged polar or a hydrophobic amino acid, but substitutions with Pro are avoided because helical structures may be destabilized by such a significant effect on secondary structure of inserting a Pro in place of another amino acid.
Substitutions with Cys are specified and may include substitution with o.-aminobutyric acid (Aba) . This non-natural amino acid is suggested to cause a super-imposition with cysteine. Its ethyl side chain is closer to being isoteric than any of the naturally occurring non-polar amino acids. In addition, it is specified that Cys can be substituted with homocysteine or diaminosuberic acid thereby retaining charge and size conformation but eliminating potential homodimerization. The chiral amino acids of the IL-8 analogs of the present invention have the L configuration. Analog 1 (Sequence I.D. No. 1) was designed as a structural mimic of IL-8 from amino acid residues 4 to 20 (Clark-Lewis et al., 1994, supra). Analog 1 contains overall homology with the amino acid sequence of human IL-8. Analog 2 (Sequence I.D. No. 2) was designated as a structural mimic of human IL-8 from amino acid residues 4 to 17. Analog 2, which has been C-terminally truncated has a slight loss of activity when compared to analog 1. Analog 12 (Sequence I.D. No. 12) was designed as a structural mimic of IL-8 from amino acid residues 6
to 20. Analog 12 contains overall homology with the amino acid sequence of human IL-8.
Analogs 13 and 25 (Sequence I.D. Nos. 13 and 25) were designated as structural mimics of human IL-8 from amino acid residues 6 to 17 (or 18) . Analog 13 has been C-terminal truncated causing a slight loss of activity when compared to analog 12.
An analog of the present invention can be made by exclusively solid phase techniques, by partial solid- phase techniques, by fragment condensation, by classical solution coupling, or, as long as the analog consists of only amino acids among the twenty naturally occurring amino acids corresponding to codons of the genetic code, by employing recombinant DNA techniques with bacteria, such as E. coli or B . subtilis; yeast, such as S. cerevisiae or P.pastoris; or insect or mammalian cells.
Methods of making a polypeptide of known sequence by recombinant DNA techniques are well-known in the art. See, e.g., U.S. Pat. No. 4,689,318, which is incorporated herein by reference.
Methods for chemical synthesis of polypeptides are also well-known in the art and, in this regard, reference is made, by way of illustration, to the following literature: Yamashino and Li, J. Am. Chem. Soc. 100:5174-5178, 1978; Stewart and Young, Solid Phase Peptide Synthesis (WH Freeman and Co. 1969) ; Brown et al., JCS Perkin I, 1983, 1161-1167; M. Bodanszky et al. , Bioorg. Chem. 2.:354-362, 1973; U.S. Pat. Nos. 4,689,318; 4,632,211; 4,237,046; 4,105,603; 3,842,067; and 3,862,925, all of which are incorporated herein by reference.
Preferred, automated, step-wise solid-phase methods for synthesis of peptides of the invention are provided in the examples below. The IL-8 analogs encompassed by the present invention have one or more of the biological activities of naturally occurring IL-8, as described above, and, as
such, are useful therapeutically in one or more of the ways in which IL-8 is known to be useful, e.g., as an anti-infective for bacterial, fungal, viral, and or protozoan infections, as an anti-neoplastic for both leukemia and solid or metastatic disease.
The biological activity of an analog of the invention is determined by comparing the analog with naturally occurring IL-8.
The analogs of the invention are employed therapeutically, under the guidance of a physician for the treatment of leukemic or solid tumors or metastatic disease and infectious diseases including but not limited to viral, bacterial, fungal, yeast or parasitic. They may also be used for the treatment of anti-inflammatory and auto immune disease. Disorders in this group include SLE, GVHD, RA, IBD, asthma and psoriasis.
The dose and dosage regiment of an analog according to the invention that is suitable for administration to a particular patient can be determined by a physician considering the patient's age, sex, weight, general medical condition, and the specific condition and severity thereof for which the analog is being administered. The physician must also determine the route of administration of the analog; the pharmaceutical carrier with which the analog may be combined; and the analog's biological activity, relative to that of naturally occurring human IL-8, in the above- described assays.
Generally, injection (intavenous, subcutaneous or transmuscular) of 1-500 μmol of analog/kg body weight, by bolus injection, by infusion over a period of about 5 minutes to about 60 minutes, or by continuous infusion is sufficient for therapeutic efficacy. Aerosol inhalation of 0.1 or 2 mg of analog/kg body weight is also sufficient for efficacy.
Intravenous, subcutaneous or intramuscular administration, by bolus injection or continuous
infusion, is preferred for use of the analogs of the invention in treatment of neoplastic, infectious, autoimmune or inflammatory diseases.
The analogs of the invention, or a pharmaceutically acceptable salt thereof, can be combined, over a wide concentration range (e.g., 0.001 to 11.0 wt %) with any standard pharmaceutical carrier (e.g., physiological saline, THAM solution, or the like) to facilitate administration by any of various routes including intravenous, subcutaneous, intramuscular, oral, or intranasal, including by inhalation.
Pharmaceutically acceptable acid addition salts of the analogs of the invention can be prepared with any of a variety of inorganic or organic acids, such as for example, sulfuric, phosphoric, hydrochloric, hydrobromic, nitric, citric, succinic, acetic, benzoic and ascorbic. The analogs can, for example, be advantageously converted to the acetate salt by dissolution in an aqueous acetic acid solution (e.g., 10% solution) followed by lyophilization.
Pharmaceutical compositions containing a compound of the present invention as the active ingredient in intimate admixture with a pharmaceutical carrier can be prepared according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., intravenous, oral or parenteral. In preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like in the case of oral liquid preparations (such as, for example, suspensions, elixirs and solutions) ; or carriers such as starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations (such as, for
example, powders, capsules and tablets) . Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar-coated or enteric-coated by standard techniques. For parenterals, the carrier will usually comprise sterile water, though other ingredients, for example, to aid solubility or for preservative purposes, may be included. Injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed. The pharmaceutical compositions will generally contain dosage unit, e.g., tablet, capsule, powder, injection, teaspoonful and the like, from about 0.001 to about 10 mg/kg, and preferably from about 0.01 to about 0.1 mg/kg of the active ingredient.
The following examples are provided to further illustrate the present invention and are not intended to limit the invention beyond the limitations set forth in the appended claims.
EXAMPLE 1 Synthesis of IL-8 Peptide Analogs. Peptides were synthesized using solid-phase methodology, generally described by Merrifield (J. Amer. Chem. Soc. .85.:2149, 1963) (see also Stewart and Young, supra) with various modifications described herein. Synthesis was carried out on an Applied Biosystems 431A automated peptide synthesizer (Applied Biosystems, Foster City, CA, USA) . Sequential assembly of a peptide analog is conducted from the carboxy-terminus, which is bonded to a solid-phase resin, to the amino terminus; the addition of amino acids to a peptide chain is automated after the attachment of the carboxy-terminal amino acid to the resin.
For peptides that have a carboxyl group at the carboxy-terminus, p-chloromethyl-derivatized polystyrene
supports are employed, and the carboxy-terminal amino acid is esterified to the support via reaction with KF. Analogs with a C-terminal proline or a penultimate C- terminal proline may be synthesized using a 2- chlorotrityl chloride derivatized resin. Attachment of FMOC amino acids to the resin can be quantitated by spectrophotometric determination at 266 nm following treatment of a weighed sample with 50% piperidine in DMF. Substitution levels for automated syntheses are preferably between 0.2 and 0.6 mmol amino acid per g resin. A typical FMOC synthesis is performed on a scale of 0.1-0.25 mmol and thus is initiated with 0.15-1.25 g amino acid-derivatized resin. The 9-Fluorenyl methoxycarbonyl (FMOC) group was used for protection of the alpha amine group of all amino acids employed in the syntheses; however, other protecting groups known in the art for alpha amines can be employed successfully. Side- chain functionalities were protected as follows: Arg with 4-Phenylazobenzyloxycarbonyl; Cys, Gin, and His with trityl; Glu, Ser, and Thr with benzyl; Lys with tertiary butyloxycarbonyl; and Tyr with tertiary butyl.
Resins employed in the syntheses were purchased with the C-terminal residue already attached to derivatized polystyrene-1% divinyl-benzene (200-400 mesh) , either by 4-hydroxymethylphenoxyacetic acid or 2- chlorotrityl chloride.
Steps in the syntheses of the IL-8 analogs employed the following Protocol 1(a) :
Mix Time # of
Step Reagent (min) Times
1 20% piperidine in NMP 16.4 2
2 0.45M HBTU/HOBT in DMF/ in 7.6 1 NMP
3 NMP 4.6 1
4 2.0M DIEA in NMP 2.2 1
5 NMP 22.2 1
6 0.5M acetic anhydride/0.125M 6.4 1 DIEA/0.015M HOBT/in NMP
7 NMP 4.6 1
8 Stop or return to step 1 for next coupling
NMP = N-Methylpyrrolidone
HBTU = 2 - (lH-benzotriazol-1-yl ) - 1 , 1 , 3 , 3 * tetramethyluronium hexafluorophosphate
HOBT - 1-Hydroxybenzotriazole
DMF = Dimethylformamide
DIEA - Diisopropylethylamine
All chemicals were reagent or peptide synthesis grade and were used as purchased. DIEA and NMP were from Fisher Scientific, Fair Lawn, NJ, USA. Piperidine, HOBT and HBTU were from Advanced ChemTech, Louisville, KY, USA. DMF was from E. Merck, Gibbstown, NJ, USA, . Acetic anhydride was from FLUKA, Buchs, Switzerland. The coupling of amino acids was carried out for 45 minutes with a four-fold excess of the activated esters of the FMOC amino acids with respect to the available amine sites on the resin.
After assembly of the completed analog, the amino-terminal FMOC group was removed using step 1 of the above protocol and then the resin was washed with methylene chloride and dried. The analogs were then deprotected and removed from the resin support by treatment with TFA for 2 hours at 25 °C. The peptide was precipitated with cold diethyl ether, the liquid phase was filtered away and the peptide was extracted with 10% acetic acid in water and lyophilized. The resulting crude preparations were purified by preparative high performance liquid chromatography (HPLC) on a Waters C-18 column (40 x 200 mm) (Millipore Corp, Millford, MA, USA) and analyzed by analytical HPLC. Preparative HPLC separations were performed with the Waters column on a Waters Delta Prep 4000 System
(Millipore Corp, Millford, MA, USA) at a flow rate of 75 ml/min. Samples were introduced in 0.1% TFA (running buffer) and after a 5 minute lag to ensure complete loading, eluted from the column with a 1%/minute acetonitrile gradient with an elution time of 24-26 minutes. Peptide fractions were monitored by UV absorbance at 220 nm. In all cases, fractions were manually collected at peak detection. The purified fractions were analyzed on an analytical HPLC System, Waters 712 WISP, using a Waters C-18 column (8 x 100 mm) using 0.1% TFA and an acetonitrile gradient. Other HPLC buffer systems which may be employed in the analytical HPLC include triethylamine phosphate (TEAP), pH 2.5-3.0, TEAP, pH 6.5, and a mixture of 0.1% phosphoric acid, 0. IM sodium perchlorate, pH 2.5 with an acetonitrile gradient. Although the TFA buffer system does not resolve microheterogeneous contaminants as well as other systems, recovery is generally 50-90% higher. A portion of a fraction from the preparative HPLC which appeared homogenous by analytical HPLC was removed, lyophilized and hydrolyzed for amino acid analysis. These portions with the proper amino acid compositions and proper mass,
determined by.matrix assisted laser desorption ionization - time of flight (MALDI-TOF) mass spectro etry, were treated to replace the TFA with acetic acid and were then subjected to bioassay. For amino acid analysis, a sample of analog was hydrolyzed in 6N HCl containing 1% phenol for 70 minutes at 110 °C. Analyses were performed by a procedure which is a modification of the method of Cohen and Michaud (Anal. Biochem 211:279-287. 1993) employing the AccQ Tag reagent (Waters, Millford, MA, USA) .
The synthesis of Analog 1 (Sequence I.D. No. 1) and Analog 12 (Sequence I.D. No. 12), both, peptides based on the IL-8 amino terminal domain, was initiated by using 581 mg of an H-LYS(BOC) 2-chlorotrityl resin (substitution level = 0.43 mmol/g) , purchased from
AnaSpec, Inc., (San Jose, CA, USA). The synthesis was carried out automatically by the ABI 431A Peptide Synthesizer. The amount of components is summarized in the following Table.
Table 4
Grams/protected
CYCLE amino acid
1 .337 P
2 .620 H
3 .387 F
4 .337 P
5 .469 K
6 .327 S
7 .494 Y
8 .341 T
9 .469 K
10 .353 I
11 .586 C
12 .612 Q
13 .586 C
14 .397 R
Upon completion of the synthesis, 1.2 g of
Analog 1 peptide-resin and 0.8 g of Analog 12 peptide- resin were obtained. These were added to 10 ml of TFA in two 100 ml round bottom flasks with 500 μl of H20 500 μl thioanisole, 250 μl ethanedithiol and 750 mg phenol and stirred at 25 °C for 2 hours. The reactions were terminated by the addition of 100 ml cold diethyl ether to precipitate the peptides. The solution was filtered and the peptides were extracted with 100 ml 10% acetic acid in water, frozen, and lyophilized. A small portion of each was dissolved in 225 μl of 0.1% TFA and injected onto the analytical HPLC using the previously described
conditions to determine elution characteristics for the preparative scale purification. The remainder of the crude peptide was loaded onto the preparative system and eluted under the above conditions. A 0-40% acetonitrile gradient over 40 minutes was used to elute the peptide components. An aliquot of homogeneous fractions from preparative HPLC was removed, and then hydrolyzed for amino acid analysis. Amino acid analysis results for Analog 1 (Sequence I.D. No. 1) preparation were as follows: Ser (1)0.96, Glx (2)1.98, His (1)1.04, Thr (1)0.94, Arg (1)1.08, Pro (2)1.82, Cys (2)1.86, Tyr (1)1.07, Lys (3)2.94, He (1)1.13, Phe (1)1.14, and Leu (1)0.98.. The MALDI-TOF mass spectrum showed the proper mass peak and only peptide-matrix peaks. Amino acid analysis of a weighed sample showed the powder to be 85.9% peptide by mass.
Amino acid analysis results for Analog 12 (Sequence I.D. No. 12) preparation were as follows: Ser (1)0.96, Glx (1)0.96, His (1)1.04, Thr (1)0.94, Arg (1)1.08, Pro (2)1.82, Cys (2)1.86, Tyr (1)1.07, Lys
(3)2.94, He (1)1.13, Phe (1)1.14. The MALDI-TOF mass spectrum showed the proper mass peak and only peptide- matrix peaks. Amino acid analysis of a weighed sample showed the powder to be 88.1% peptide by mass.
EXAMPLE II Administration of IL-8 Peptide Analogs affects Ca+ Mobilization in PMNs. Polymorphonuclear leukocytes (≥95% neutrophils, PMNs) were isolated from heparinized (10 U/ml) blood collected from healthy volunteers.
Erythrocytes were removed by 6% dextran sedimentation for 30 minutes at room temperature, and then the supernatant was subjected to Ficoll (Ficoll-Paque, Pharmacia LKB, Uppsala, Sweden) density gradient centrifugation. PMNs were obtained from the pellet. Contaminated erythrocytes were eliminated by one cycle of hypotonic lysis. After an additional washing step, the cells were counted and
adjusted to a final concentration of 5xl06/ml in RPMI 1640 (Gibco, Grand Island, NY) .
Fluo-3 Loading - The loading procedure with Fluo-3 (Molecular Probes, Eugene, OR) was carried out with PMNs suspended at a density of 5xl06/ml in fresh RPMI 1640 containing 2.0 μM Fluo-3 AM (prediluted in dimethyl sulfoxide; Sigma Chemicals) in polypropylene tubes (Falcon 2063, Becton Dickinson) . PMNs were incubated for 25 minutes at 37 °C in a 5% C02 incubator. During the incubation period, the PMNs were gently agitated twice. To remove extracellular Fluo-3 AM, cells were washed twice with RPMI 1640 and with Ca2+ and Mg2+ - free phosphate-buffered saline (PBS) containing 100 mM KCl and 5 mM HEPES buffer at pH 7.05. Finally, the cells were adjusted to a density of 5xl05/l00 μl in the PBS buffer and resuspended in 5 x 35 mm tubes. The samples were kept in the dark at room temperature until use. Measurement of [Ca2+] in Flow Cytometry - Before addition of the stimuli the fluorescence channel of the FACScan Plus (Becton Dickinson) was adjusted to find the basal fluorescence level of loaded but unstimulated PMNs. The samples were excited by an argon laser at 488 nm and emission was measured at 525 nm (green fluorescence, channel FL1) . The temperature has no effect on the appearance of neutrophil subpopulations with different [Ca2+] mobilizations. However, the experiments were carried out at room temperature, 22°C. PMNs were then stimulated at different concentrations with full-length IL-8/NAP-1 or experimental polypeptide analogs. The events were acquired before and 5 s after addition of the stimuli, and acquisition was continued over 80 s. For each acquisition 2500-3000 events were collected in 6 s interrupted for a time interval of 8 s or less using the FACScan software (Becton Dickinson) . The fluorescence of Fluo-3-loaded cells was measured in arbitrary fluorescence units of mean channel fluorescence (channel FL1) . To control the influence of the medium, PBS
(supplemented as described above) was added instead of stimuli. A continuous measurement of unstimulated PMNs was also carried out. Both procedures did not result in an increase in arbitrary fluorescence units. Analog 1 (Sequence I.D. No. 1) exhibits agonist activity on PMNs: Prior studies of IL-8/NAP-1 have demonstrated that this cytokine induces an increase in Ca+ after stimulation of neutrophils. Figure IB demonstrates the effect of the 77 amino acid IL-8 at 10"6M on neutrophil Ca+ release as measured and described above. Figure 1A shows unstimulated neutrophils. Figure 2A again shows unstimulated neutrophils whereas Figure 2B shows the lack of effects by the excipient alone. Treatment with Analog 1 induced a change in neutrophil Ca+ concentration as shown in Figure 3B relative to untreated cells in Figure 3A. The data show that the majority of neutrophils showed an essentially identical increase in calcium concentration upon addition of either IL-8/NAP-1 or Analog 1. Analog 12 (Sequence I.D. No. 12) exhibits antagonist activity on PMNs: As shown in figure IB, treatment of neutrophils with native IL-8/NAP-1 leads to an increase of arbitrary fluorescence units as compared to excipient treated Fluo-3 loaded neutrophils (figure 2B) . However, as shown in Figure 4B, when the PMN's were pre-incubated with both native IL-8 and analog 12 at 10"6 M, analog 12 blocked the appearance of the Ca+ signal induced by IL-8 as shown in Figure IB.
EXAMPLE III
In vivo Bioreactivity Assay of IL-8 Analogs with Agonist Activity. A stock solution of 5 mg/ml of Analog 1 was prepared using Dulbelcco's phosphate buffered saline D-PBS. The solution was made 5x to compensate for the injection of 0.2 ml intraperitoneally (i.p) . The mice were treated at various times with various doses of Analog 1 (Sequence I.D. No. 1). In
addition, control animals were injected with excipient only.
The mice used for the study were C57BL/6 females, which were obtained from Jackson Laboratories. The animals were 8-10 weeks of age and weighed 15-18g. The mice were housed in conventional cages, fed pelleted food and given water ad libi tum.
At various times following injection, the mice were bled from the retinal orbital plexus and the blood (40 μl) was collected into heparinized capillary tubes. The blood was then analyzed using a Serona Baker 9000 Blood analyzer. In addition, blood films were made and differentials undertaken on at least 200 cells/sample.
The mice were sacrificed by ether overdose, the ventral skin reflected and the peritoneum lavaged with three 5 ml lavages of calcium-, magnesium-free HBSS. At one, two, four, eight and 24 hours, following injection, three to five mice and/or control mice were lavaged and the cells collected in 15 ml tubes. The peritoneal cells were then centrifuged and counted. In addition, a differential was done on the peritoneal cells in a cytospin preparation. For the cytospin, 25 μl of bovine albumin (Sigma Lot #70H0183) was first placed in the bottom of the chamber, and 100 μl of cell suspension (100,000 cells) added. The chambers were spun at 1000 rpm for 5 minutes and left to dry. They were then placed in leukostat fixative solution for 5 seconds followed by 45 seconds in Leukostat solution 1 and 45 seconds in Leukostat solution 2. Fixed cells were washed in deionized H20 for 5 seconds and allowed to dry. The slides were analyzed under a microscope for differentials.
Analog 1 is an agonist with biological activity in in vivo assays. The in vivo chemotactic activity for cells into both the peritoneum and PBL are shown in this data set. Figure 5 shows the effect of a single i.p. injection of Analog 1 on peritoneal cellularity when
employed in increasing concentrations from 0.1-500 μg/animal. Optimal activity was observed at 10 μg/animal. Similarly, a significant increase in PBL cellularity (Figure 6) was observed with maximal activity at 0.1 and 10 μg/animal. The primary cell type elicited in the peritoneum by the i.p. injection of Analog 1 was PMNs as shown in Figure 7. Treatment with Analog 1 resulted in a four-fold increase in PMNs in the peritoneum and an almost two-fold increase in monocyte/macrophages (Figure 8) . Similarly, there was an increase in the frequency of PMNs in the peripheral blood (Figure 9) with a concomitant significant increase in the absolute number of PMNs and monocytes in the peripheral blood (Figure 10) . Analog 1, having residues 4-20 of human IL-8, was synthesized according to the method described herein (Example 1) . Figure 11 shows the kinetics of the in vivo chemotactic response in the peritoneum following i.p. injection of 10 μg of this peptidal low molecular weight analog. As mentioned previously, the greatest increase observed was in the number of macrophages and PMNs in the peritoneum.
These results are substantially identical to nonhuman primate studies which demonstrated the hematologic effects of native IL-8 following parenteral administration. IL-8 was administered by both push and continuous infusion to baboons. This resulted in a granulocytosis which persisted as long as IL-8 remained detectable within the circulation (Van Zee, K.J. et al. , J. Immunol. 148:1746-1752, 1992) . Similar results have been observed in rabbits where natural IL-8 was injected intradermally in the presence of a vasodilator substance. In those studies, IL-8 induced a neutrophil accumulation that was fast in onset, relatively short in duration and was associated with a parallel time course of plasma protein extravasation (Rampart, M. , Am. J. Pathol. 135-.21-25, 1989). Thus, the polypeptide Analog 1 of the
present invention elicits essentially the same biological responses in vivo as naturally-occurring IL-8.
EXAMPLE IV In vivo Bioassay of IL-8 Analogs with
Antagonist Activity. A stock solution of 5 mg/ml of Analog 12 (Sequence I.D. No. 12) was prepared in D-PBS. Analog 12 consists of 88.1% active peptide and the calculations were adjusted to compensate for the activity of Analog 12. Serial dilutions were then made resulting in solutions of appropriate doses of analog 12 in 0.2 ml. The animals were injected intraperitoneally with 0.2 ml of the appropriate solution 1 hour prior to arachidonic acid application. The study consisted of various dosage groups as well as excipient groups as contols.
The animals used for the study were C57BL/6 females, which were obtained from Jackson Laboratories (age 8 weeks and weight 15-18g) . The mice were housed in conventional cages, fed pelleted food and given water ad libi tum.
The arachidonic acid (Sigma Lot #42H7817) was dissolved in methyl alcohol resulting in a final concentration of 2 mg/20μl. At time zero, 10 μl of arachidonic acid was applied to each side of the test ear using a pipettor. Each mouse received a total of 2 mg and a total volume of 20 μl. One hour post challenge, the test and control ears were measured for thickness using a Mitutoyo No. 7300 gauge caliper. The thickness was recorded in units of 0.001 inches. To determine the total edema, the measurement of the control ear was subtracted from the test ear measurement (arachidonic acid ear) .
Analog 12 is an antagonist with in vivo bioactivity. The effect of Analog 12 on arachidonic acid-induced ear inflammation was evaluated in vivo . In this model, the application of arachidonic acid to the
pinna of mice induces an immediate PMN-associated erythema and edema which may be measured by change in thickness. As shown in Figure 11, the administration of Analog 12 blocked edema with an approximate EC-50 of 1 μg/animal. In other recent studies in our laboratory similar suppression of arachidonic acid induced inflammation in the mouse pinna was observed with 100 mg/kg phenidone (NSAID) .
These results are substantially the same as these reported in International Application No.
PCT/CA92/00528. In that study, N-terminally truncated natural IL-8 (70 amino acids) was shown to inhibit inflammation using the rabbit plasma exudate dermal assay reported by Beaubien et al. (Biochem. J. , 1990, 271:801) . In that model, anti-inflammatory activity is monitored by a reduced edema formation and neutrophil accumulation in rabbit skin. In contrast to the large IL-8 analog described in PCT/CA92/00528, Analog 12 described in this example is a 14 amino acid IL-8 analog. The analog described in the aforementioned patent is a much longer antagonist which comprises approximately 45 amino acids of IL-8. These analogs require extensive synthesis and/or recombinant production which substantially increases both the cost of the goods and the probability of synthetic errors during manufacturing.
EXAMPLE V
Chemokines form a superfamily that is divided into two distinct functional classes: alpha and beta. All the members of each class share an organizing primary sequence motif. Alpha family members are distinguished by the C-X-C motif - where the first two cysteines of the motif are separated by an intervening residue. C-X-C chemokines are potent chemoattractants and activators for neutrophils. The beta family chemokines have a C-C motif and are equally potent chemoattractants and activators of monocytes. However, other roles are rapidly emerging for
chemokines as well. Thus, both alpha and beta chemokines, have been shown to attract both memory T-cell and eosinophils as well as trigger the release of histamine from basophils. Edgington, discussed (Edgington et al. ,
Biotech. 11.:676, 1993) the potential to design site specific inhibitors and/or agonists for the chemokines. He states that most researchers believe that the greatest promise lies in creating small molecular peptides or mimetics that will compete with natural molecules for the chemokine binding sites. Because both the ligand and the receptor binding site are relatively small, drug designers have focused on understanding where the critical contact points lie that turn on the receptor signal transduction machinery. Many of these investigators believe that similarities in sequence will also yield structural similarities. Dr. Daniel Witt of Repligen, Cambridge, MA is quoted in the article as saying "If you have 15 different receptors and you know the crystal structure for two you can expect the structural model will hold true for all." It was suggested that both chimeric ligands and receptors should fold properly and yield data about critical contact points. "As a system, it is about everything you could ask for imposing structural-functional questions" i.e., there is strong homology amongst the receptors and ligands of the chemokines which will facilitate rational drug design. It is clear that existing drugs have been synthesized which target similar membrane spanning receptors including: histamine inhibitors, beta blockers, and serotonin receptors which have all yielded receptor antagonists to date.
"Receptor promiscuity" presents one problem to drug design of the chemokines. Within chemokine families, individual receptors bind multiple ligands. Determining chemokine structure and function after dispensing with the dogma of "one ligand, one receptor"
is extremely difficult, especially when target cells contain an ensemble of receptors on their membrane. For example, there are at least three kinds of chemokine receptors involved in binding the beta chemokines MCP-1, MlP-lα/1 and RANTES. Based on studies to date, one receptor binds all three ligands, another binds only MIP- l /β and a third only binds MCP-1. Similar observations of receptor/1igand promiscuity are seen with the alpha chemokines. High affinity binding to neutrophils is observed for IL-8; however, evidence for high and low affinity binding receptors is observed with NAP-2, ENA-78 and MGSA. Two closely related neutrophil derived IL-8 receptors, type A and type B, have been cloned whose binding characteristics could account for the binding observed with neutrophils: Type A receptors have a high affinity for IL-8 and low affinity for MGSA and NAP-2. The type B receptors bind IL-8 and MGSA with high and NAP-2 with intermediate affinity. However, it remains possible that more than two IL-8 receptors exist and are expressed on neutrophils. DNA sequence data and X-ray diffraction data will facilitate rational drug design. Based on this knowledge, efficacious peptide analogs can be synthesized and assayed in the assays specified herein.
EXAMPLE VI Platelet factor 4 (PF-4) is carried within the alpha granules of platelets in the form of a non-covalent complex. PF-4 is a tetramer of four identical polypeptide chains, each of which contains 70 residues in the human moieties. When released into the plasma from activated platelets, PF-4 attracts white blood cells i.e., neutrophils and monocytes and it's release may be a signal that is involved in inflammation. Other possible functions of PF-4 derive from a strong binding to negatively charged polysaccharides especially heparan and heparin for which it has a dissociation constant of 10"7-5.
The ability of PF-4 to neutralize heparin and related polymers is of general interest because heparin has been shown to interact with over 50 different enzymes to suppress muscle growth and to accelerate angiogenesis in solid tumors. PF-4 has recently been patented as
Oncostatin A for its ability to inhibit tumor growth. It has also been shown to reverse immunosuppression in mice.
PF-4 also binds tightly and preferentially to double stranded DNA in vi tro. This binding probably does not occur in vivo but it might be an important attribute of several recently discovered growth related proteins which are homologous to PF-4. Members of this class are 1) induced by IFN-γ, 2) constitutively overexpressed in Chinese hamster and human cell lines, 3) strongly induced by Rous sarcoma virus and fibroblast cells and 4) over expressed in stimulated leukocytes.
In contrast to many of the other alpha chemokines, PF-4 does not induce comparable neutrophil responses although chemotaxis and exocytosis have been reported with concentrations that were 1,000 to 10,000- fold higher than those required for IL-8.
PF-4 crystallizes as a tetramer, although the monomer structure is similar to that of IL-8. In solution, human PF-4 is in equilibrium among monomers, dimers, and tetramers. PF-4 and IL-8 share 35% sequence identity, including the four cysteines. Molecular modeling studies suggest that a similar folding pattern will be found for all members of the C-X-C family. Even MCP which belongs to the C-C family (beta chemokine) , has been found to have the same tertiary structure. Thus, it will be possible to sequence an agonist for PF4 in accordance with the present invention.
EXAMPLE VII Platelet basic protein (PBP) is a highly specific platelet alpha granular protein that is a precursor of low affinity platelet factor 4 (LA-PF4) and
beta thromboglobulin (3TG) . These proteins differ only in amino terminal amino acid sequence and isoelectric point. PBP is synthesized by megakaryocytes, contains 94 amino acids and is converted to LA-PF4 which contains 85 amino acid residues within megakaryocyte and platelet granules. jSTG itself (81 amino acid residues) as originally described cannot be detected in cell lysates prepared using trichloroacetic acid. It probably results from amino terminal cleavage of LA-PF4 or PBP after cell secretion. Production of 3TG from PBP and LA-PF4 can be demonstrated in vi tro by incubating the platelet release supernatant at 37°C or by limited cleavage with plasmin or trypsin. The three forms of βTG antigen are immunologically identical when using rabbit polyclonal antibodies. The biological activities of PBP and it's derivatives are not well understood. It has been proposed that LA-PF4 [also referred to as connective tissue activating peptide III (CTAP-III)] is a weak mitogen for connective tissue fibroblasts. It has also been reported that 3TG antigen promotes chemotaxis in fibroblasts. In recent studies, it was observed that a cleavage product of βlG called neutrophil activating peptide (NAP-2) was formed in cultured and stimulated mononuclear cells and is a potent activator of human neutrophils. NAP-2 is a 78 amino acid peptide corresponding to the major carboxy-terminal fragment of 0TG. It has 46% homology with NAP-l/IL-8. NAP-2 behaves as a typical chemotactic receptor agonist, inducing cytosolic free Ca+ changes, chemotaxis, and exocytosis while PBB, LA-PF4 and PF4 have little such activity. It should be noted, as discussed above, that NAP-2 also interacts with the NAP-l/IL-8 receptors. Thus, in accordance with the present invention, it should be possible to synthesize agonists for NAP-2, including those that bind to the IL-8 beta receptor.
EXAMPLE VIII
IP-10 was originally isolated as a predominant messenger RNA form induced by IFN-γ or LPS in monocytes and its expression has been detected in vivo during the development of a delayed type hypersensitivity cellular immune response by monocytes, endothelial cells, and infiltrating mononuclear cells. In addition, IP-10 expression has been seen in the epidermis, dermis and cutaneous lesions of psoriasis, tuberculoid leprosy, and fixed drug eruptions.
IP-10 is a member of the chemokine superfamily and is approximately 30% homologous to IL-8 and PF-4. Recent studies have shown that IP-10 can elicit an anti- tumor inflammatory response that is capable of inhibiting the growth of plasmacytoma and mammary adenocarcinoma in immunocompetent mice. This effect is thymus dependent suggesting that IP-10 might act on T-cells. In addition, a neutrophil, and monocytic accumulation is seen as a result of IP-10 expression in immunocompetent but not nude mice. IP-10 does not have an ELR motif. ELR incorporation into IP-10 is not sufficient for IL-8 receptor interaction or neutrophil activation and suggests that IP-10 has a different receptor ligand conformation. However, hybrids formed between IL-8 and IP-10 could be designed which demonstrate that essential receptor binding motifs from the IL-8 sequence could be structured within the IP-10 molecule allowing IL-8 binding.
Recent reports have shown that IP-10 is expressed by activated but not by resting T-hybridoma cells, normal T-cells and thymocytes. While resting lymphocytes did not synthesize IP-10, a high level of IP- 10 transcripts are found in lymphoid organs (spleen, thymus, and lymph nodes) . Thymic and splenic stromal cells constitutively express high levels of both IP-10 messenger RNA and protein accounting for the high level of spontaneous expression in lymphoid tissue. Therefore,
in addition to its role as a pro-inflammatory cytokine, IP-10 may participate in T-cell effector function of perhaps T-cell development. IP-10 expression has also been shown to be induced in delayed type contact hypersensitivity in sensitized animals. Thus, in accordance with present invention, we will be able to synthesize agonists for IP-10.
EXAMPLE IX Human tumors can constitutively express cytokines and growth factors. Melanoma cells constitutively express GRO-ot, which is also termed "melanoma growth stimulatory" activity. Similarly, GRO-αr is expressed in human colon tumors along with GRO-3 and GRO-7. These three genes, GRO-ot, GR0-/3, and GRO-7, are closely linked on chromosome 4. GRO- * and GRO-7 show 90 and 86% sequence homology with GRO-α. The GRO-α/MGSA alpha chemokine has potent chemotactic, growth regulatory and transformative functions. The function of GR0-3 and GRO-7 is unknown. GRO-α messenger RNA is selectively overexpressed in psoriasic epidermis and is reduced by therapy with Cyclosporin-A. It has been suggested that this over expression is a karyotinocyte response to activated T-cells in psoriasis. GRO-α/MGSA has been localized in a variety of cutaneous lesions. A raised level of immunoreactive GRO-αMGSA in diseased epidermis is detected in verruca vulgaris followed by psoriasis, keratoacanthoma, and squamous cell carcinoma. Detection of GRO-ot in basal cell carcinoma is variably present in the sclerosis variant and absent in the more common nodular variant. Thus, in accordance with the present invention, we will be able to synthesize agonists for GRO-α, β , and 7.
EXAMPLE X
Recently, another alpha chemokine has been discovered and has been called ENA-78 (epithelial cell
derived neutrophil activator) . ENA-78 shows significant amino acid sequence homology with NAP-2 (53%) , GRO-α (52%) , and IL-8 (22%) . ENA-78 appears to activate neutrophils through the IL-8 receptor. ENA-78 has been cloned in pigs and was initially described as alveolar macrophage derived chemotactic factor 2. It shares 53% sequence homology with human NAP-2 and 61% sequence homology with the GRO-related proteins. It also has 67% sequence homology with the 78 amino acid ENA-78 and is felt to represent the porcine variant thereof. ENA-78 was initially identified in the conditioned medium of stimulated human epithelial cell line A549. It is produced in response to stimulation with either IL-13 or TNF-α and is produced and secreted concomitantly with IL- 8, GRO-α, and GRO-7. ENA-78 consists of 78 amino acids and has a molecular weight of 8357. The four cysteines are positioned identically to those of IL-8 and similar analogues. ENA-78 stimulates neutrophils, induces chemotaxis, a rise in intracellular-free Ca+ and exocytosis. Cross desensitization experiments indicate that ENA-78 acts through the same type of receptors as IL-8, NAP-2 and GRO-α. Thus, in accordance with the present invention, we will be able to synthesize agonists for ENA-78, including a peptide analog that binds to the IL-8 receptor.
EXAMPLE XI
Recombinant human IL-8 was obtained from Bachem and radioiodinated with IODOGEN, (Pierce, IL) . Following purification by column chromatography, the radioligand was used in competitive binding assays using non- radiolabeled peptide analogs of the present invention. Analogs with the following sequences were synthesized and used as competitors. Parallel competitive binding studies were performed with the same analogs using another radiolabeled chemokine, Gro-α. The analogs used for this Example include Analogs 12 and 23-25, Sequence
I.D. Nos. 12, 23, 24, 25) and were synthesized according to procedures set forth in Example 1.
Analog 12 (Sequence I.D. No. 12) : Derived from IL-8 (this analog is sometimes referred to as "XXR")
Arg-Cys-Gln-Cys-He-Lys-Thr-Tyr-Ser-Lys-Pro-Phe-His- Pro-Lys
Analog 23 (Sequence I.D. No. 23): Derived from IL-8 (this analog is sometimes referred to herein as "CVC")
Arg-Cys-Val-Cys-He-Lys-Thr-Tyr-Ser-Lys-Pro-Phe-His- Pro-Lys
Analog 24 (Sequence I.D. No. 24): Derived from 11-8 (this analog is sometimes referred to herein as "CMC")
Arg-Cys-Met-Cys-He-Lys-Thr-Tyr-Ser-Lys-Pro-Phe-His- Pro-Lys
Analog 25 (Sequence I.D. No. 25): Derived from IL-8 (this analog is sometimes referred to as "FH")
Arg-Cys-Gin-Cys-He-Lys-Thr-Tyr-Ser-Lys-Pro-Phe-His
The data in Figure 13 demonstrate the ability of the above-listed IL-8 peptide analogs to compete with radiolabeled native IL-8 for binding to the IL-8 receptor. Certain analogs displace radiolabeled ligand more efficiently than others. The specific binding of radiolabeled IL-8 is reduced to less than 50% in the presence of lO^M CMC (Figure 13C) . CVC demonstrates a similar displacement curve (Figure 13B) . 50% of radiolabeled IL-8 is displaced in the presence of 10"3 M XXR analog. The FH analog competes only slightly for binding to the IL-8 receptor. In fact, 50% displacement of radiolabeled IL-8 is not observed at the concentrations of competitor assayed.
Parallel studies were performed using radiolabeled Gro-α. As in competition studies with IL-8, the data show that certain analogs compete more efficiently than others for binding. As before, CVC and CMC compete most efficiently, displacing 50% of bound radiolabeled Gro α at approximately 10'5 M (Figure 14, B & C) . FH (Figure 14 D) competes slightly more efficiently than XXR (Figure 14 A) with 50% of radiolabeled Gro-α being displaced at approximately 10"4 M as opposed to 10'3 M.
The Ki's were calculated using Prism and data pooled from multiple studies using percent inhibition. The results are shown in Table 5.
Table 5
IL-8 Gro-α
IL-8 6.94 x 10-10 9.27 x 10'10
Gro-α 6.67 x lo-10 4.02 x 10-11
XXR (Analog 21) 6.67 x lo-4 1.42 x 10"4
CVC (Analog 22) 8.80 x lo-5 2.07 x 10"6
CMC (Analog 23) 6.76 x 10"5 1.59 x 10"6
FH (Analog 24) 4.50 x lo-4 7.50 x 10"5
EXAMPLE XII
The agonistic peptide analogs of the invention can act as immunostimulants in a manner similar to naturally occurring alpha chemokines, and may be useful as a protective agent for the immune system during chemotherapy and radiation therapy. Experiments were performed to determine if treatment of animals with Analog 1 could confer protection from myelosuppressive doses of gamma irradiation.
The animals used for the study were C57BL/6 females, which were obtained from Jackson Laboratories (age 8 weeks and weight 15-18g) . The mice were housed in conventional cages, fed pelleted food and given water ad libitum.
For the experiments, the mice were administered Analog 1 continuously at a rate of 1 μl/mouse over a 24- hour period. During that time they were administered a dosage of 700 rads of gamma radiation from a cobalt source. Mice that received the Analog 1 treatment exhibited accelerated myeloid restoration following irradiation, as compared to mice that received a treatment of excipient only.
While the invention has been disclosed in this patent application by reference to the details of preferred embodiments of the invention, it is to be understood that this disclosure is intended in an illustrative rather than in a limiting sense, as it is contemplated that modifications will readily occur to those skilled in the art, within the spirit of the invention and the scope of the appended claims.
Claims
1. A peptide less than about 30 amino acids in length, having agonistic activity for alpha chemokines, said peptide comprising an amino acid sequence having the formula:
Glu-Leu-Arg-Cys-Xaa,-Cys-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-
A3Sg ~ Λ33.Q — Λ3.3.1Λ** A3.3ι ι "XclcLi 2
Xaa is He, or Val;
Xaa3 is Lys, Gin, or Ser; Xaa4 is Thr, or lie;
Xaa5 is Tyr, Leu, Met, His, Val, or Thr;
Xaa6 is Ser, Gin, Thr, or Ala;
Xaa7 is Lys, Arg, or His;
Xaa8 is absent or is Pro, Phe, or Gly; Xaa9 is absent or is Phe, He, or Val;
Xaa10 is absent or is His, Lys, or Arg;
Xaan is absent or is Pro, Leu, or Phe; and
Xaa12 is absent or is Lys, His or Arg.
2. The peptide of claim 1, wherein one cysteine is substituted by an amino acid selected from the group consisting of alpha aminobutyric acid, homocysteine and diaminosuberic acid.
3. The peptide of claim 1, wherein both cysteines are substituted by an amino acid selected from the group consisting of aminobutyric acid, homocysteine and diaminosuberic acid.
4. The peptide of claim 1, wherein said peptide comprises a sequence selected from the group consisting of: Glu-Leu-Arg-Cys-Gln-Cys-Ile-Lys-Thr-Tyr-Ser-Lys-Pro-Phe- His-Pro-Lys (Sequence I.D. No. 1) ,*
Glu-Leu-Arg-Cys-Gln-Cys-He-Lys-Thr-Tyr-Ser-Lys-Pro-Phe (Sequence I.D. No. 2) ; Glu-Leu-Arg-Cys-Gln-Cys-Leu-Gln-Thr-Leu-Gln-Gly-Ile-His-
Pro-Lys (Sequence I.D. No. 3) ,*
Glu-Leu-Arg-Cys-Gln-Cys-Leu-Gln-Thr-Leu-Gln-Gly-He-His-
Leu-Lys (Sequence I.D. No. 4) ,*
Glu-Leu-Arg-Cys-Gln-Cys-Leu-Gln-Thr-Met-Thr-Gly-Val-His- Leu-Lys (Sequence I.D. No. 5) ;
Glu-Leu-Arg-Cys-Gln-Cys-Leu-Gln-Thr-Leu-Gln-Gly-His-Leu-
Lys (Sequence I.D. No. 6) ;
Glu-Leu-Arg-Cys-Met-Cys-He-Lys-Thr-Thr-Ser-Gly-He-His-
Pro-Lys (Sequence I.D. No. 7) ,* Glu-Leu-Arg-Cys-Gln-Cys-Ile-Ser-Thr-His-Ser-Lys-Phe-He-
His-Pro-Lys (Sequence I.D. No. 8) ;
Glu-Leu-Arg-Cys-Gin-Cys-He-Lys-Thr-Tyr-Ser-Lys-Pro-Phe-
His-Pro-His (Sequence I.D. No. 9) ,*
Glu-Leu-Arg-Cys-Gln-Cys-Leu-Gln-Thr-Val-Ala-Gly-He-His- Phe-Lys (Sequence I.D. No. 10) ; and
Glu-Leu-Arg-Cys-Val-Cys-Leu-Gln-Thr-Thr-Gln-Gly-Val-His-
Pro-Lys (Sequence I.D. No. 11) .
5. The peptide of claim 1, wherein said amino acid sequence further comprises an N-terminal extension having the sequence Ser-Ala-Lys.
6. The peptide of claim 1, wherein said amino acid sequence further comprises a C-terminal extension of between one and ten amino acids.
7. A peptide less than 30 amino acids in length, having agonistic activity for alpha chemokines, said peptide comprising an amino acid sequence substantially equivalent to Sequence I.D. No. 26, starting at residue 4 and continuing to residue 17.
8. The peptide of claim 7, which further comprises residues 18, 19 and 20 of Sequence I.D. No. 1.
9. A pharmaceutical composition comprising the peptide of claim 1 combined with a pharmaceutically acceptable carrier.
10. The pharmaceutical composition of claim 9, which further comprises at least one other ingredient effective for treatment of a pathological condition.
11. The pharmaceutical composition of claim 10, wherein said ingredient is selected from the group consisting of antibiotics, antivirals, antifungals, antiparasitics and anti-neoplasties.
12. A method for the treatment of a pathological condition selected from the group consisting of viral infection, bacterial infection, fungal infections, yeast infection, parasitic infection, arthritis, leukemia and solid tumor including both primary and metastatic diseases, said method comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 9, 10 or 11.
13. A peptide less than about 30 amino acids in length, having antagonistic activity for alpha chemokines, said peptide comprising an amino acid sequence having the formula:
Arg-Cys-Xaa1-Cys-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaag- Xaaj-XaajQ-Xaajj-Xaa1
wherein Xaaj is Gin, Met, or Val;
Xaa2 is He, or Val;
Xaa3 is Lys, Gin, or Ser; Xaa4 is Thr, or lie ;
Xaa5 is Tyr, Leu, Met, His, Val, or Thr; Xaa6 is Ser, Gin, Thr, or Ala; Xaa7 is Lys, Arg, or His; Xaa8 is absent or is Pro, Phe, or Gly; Xaa9 is absent or is Phe, He, or Val; Xaa10 is absent or is His, Lys, or Arg; Xaan is absent or is Pro, Leu, or Phe; and Xaa12 is absent or is Lys, His or Arg.
14. The peptide of claim 13, wherein one cysteine is substituted by an amino acid selected from the group consisting of alpha aminobutyric acid, homocysteine and diaminosuberic acid.
15. The peptide of claim 13, wherein both cysteines are substituted by an amino acid selected from the group consisting of aminobutyric acid, homocysteine and diaminosuberic acid.
16. The peptide of claim 13, wherein said peptide comprises a sequence selected from the group consisting of:
Arg-Cys-Gin-Cys-lie-Lys-Thr-Tyr-Ser-Lys-Pro-Phe-His-Pro- Lys (Sequence I.D. No. 12);
Arg-Cys-Gin-Cys-He-Lys-Thr-Tyr-Ser-Lys-Pro-Phe (Sequence I.D. No. 13) ;
Arg-Cys-Gln-Cys-Leu-Gln-Thr-Leu-Gln-Gly-Ile-His-Pro-Lys (Sequence I.D. No. 14); Arg-Cys-Gln-Cys-Leu-Gln-Thr-Leu-Gln-Gly-He-His-Leu-Lys (Sequence I.D. No. 15) ;
Arg-Cys-Gln-Cys-Leu-Gln-Thr-Met-Thr-Gly-Val-His-Leu-Lys (Sequence I.D. No. 16) ;
Arg-Cys-Gln-Cys-Leu-Gln-Thr-Leu-Gln-Gly-His-Leu-Lys (Sequence I.D. No. 17);
Arg-Cys-Met-Cys-Ile-Lys-Thr-Thr-Ser-Gly-He-His-Pro-Lys (Sequence I.D. No. 18) ; Arg-Cys -Gln-Cys- Ile-Ser-Thr-His-Ser-Lys -Phe - He -His - Pro-
Lys (Sequence I.D. No. 19) ;
Arg-Cys-Gln-Cys-He-Lys-Thr-Tyr-Ser-Lys-Pro-Phe-His-Pro-
His (Sequence I.D. No. 20) ; Arg-Cys-Gln-Cys-Leu-Gln-Thr-Val-Ala-Gly-He-His-Phe-Lys (Sequence I.D. No. 21);
Arg-Cys-Val-Cys-Leu-Gln-Thr-Thr-Gln-Gly-Val-His-Pro-Lys
(Sequence I.D. No. 22);
Arg-Cys-Val-Cys-He-Lys-Thr-Tyr-Ser-Lys-Pro-Phe-His-Pro- Lys (Sequence I.D. No. 23);
Arg-Cys-Met-Cys-He-Lys-Thr-Tyr-Ser-Lys-Pro-Phe-His-Pro-
Lys (Sequence I.D. No. 24) ; and
Arg-Cys-Gin-Cys-He-Lys-Thr-Tyr-Ser-Lys-Pro-Phe-His
(Sequence I.D. No. 25) .
17. The peptide of claim 13, wherein said amino acid sequence further comprises an N-terminal extension of between one and two non-polar amino acids.
18. The peptide of claim 13, wherein said amino acid sequence further comprises a C-terminal extension of between one and ten amino acids.
19. A peptide less than 30 amino acids in length, having antagonistic activity for alpha chemokines, said peptide comprising an amino acid sequence substantially equivalent to Sequence I.D. No. 26, starting at residue 6 and continuing to residue 17.
20. The peptide of claim 19, which further comprises residues 18, 19 and 20 of Sequence I.D. No. 26.
21. A pharmaceutical composition comprising the peptide of claim 13 combined with a pharmaceutically acceptable carrier.
22. The pharmaceutical composition of claim
21, which further comprises at least one other ingredient effective for treatment of a pathological condition.
23. The pharmaceutical composition of claim
22, wherein said ingredient is selected from the group consisting of NSAIDS, sterum, cytotoxic drugs, cyclosporins, anti-inflammatory agents, antiarthritics and anti-autoimmune agents.
24. A method for the treatment of a pathological condition selected from the group consisting of acute and chronic inflammation, auto-immune disease, arthritis, IBD, SLE, psoriasis and reperfusion injury, said method comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 21, 22 or 23.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU36817/95A AU3681795A (en) | 1994-09-23 | 1995-09-22 | Polypeptide agonists and antagonists of human interleukin-8 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31138094A | 1994-09-23 | 1994-09-23 | |
US08/311,307 | 1994-09-23 | ||
US08/311,307 US5627156A (en) | 1994-09-23 | 1994-09-23 | Polypeptide agonists for human interleukin-8 |
US08/311,380 | 1994-09-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996009062A1 true WO1996009062A1 (en) | 1996-03-28 |
Family
ID=26977840
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1995/012099 WO1996009062A1 (en) | 1994-09-23 | 1995-09-22 | Polypeptide agonists and antagonists of human interleukin-8 |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU3681795A (en) |
WO (1) | WO1996009062A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997000893A1 (en) * | 1995-06-20 | 1997-01-09 | Chiron Corporation | Interleukin-8 receptor binding compounds |
WO1998001150A1 (en) * | 1996-07-05 | 1998-01-15 | Virocell, Inc. | Interleukin-8 as an antiviral and antitumor agent |
EP0807439A3 (en) * | 1996-05-14 | 1998-03-11 | Smithkline Beecham Corporation | Method of treating sepsis and adult respiratory distress syndrome |
US6174995B1 (en) | 1994-08-23 | 2001-01-16 | Haodong Li | Human chemokines, CKβ4 and CKβ10/MCP-4 |
US6391589B1 (en) | 1994-08-23 | 2002-05-21 | Human Genome Sciences, Inc. | Human chemokine beta-10 mutant polypeptides |
WO2001072830A3 (en) * | 2000-03-31 | 2002-06-20 | Ipf Pharmaceuticals Gmbh | Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using a specific chemokine receptor analysis and the chemokine receptor-ligand interaction |
US6458349B1 (en) | 1995-06-02 | 2002-10-01 | Human Genome Sciences, Inc. | Chemokine β-4 polypeptides |
WO2005040210A3 (en) * | 2003-10-22 | 2005-06-23 | Applied Research Systems | Novel cxcl8 antagonists |
WO2006101439A1 (en) * | 2005-03-23 | 2006-09-28 | Astrazeneca Ab | Screen |
US7375192B2 (en) | 2002-05-01 | 2008-05-20 | Human Genome Sciences, Inc. | Antibodies that specifically bind to chemokine beta-4 |
US9133273B2 (en) | 2010-11-19 | 2015-09-15 | Eisai R&D Management Co., Ltd. | Nucleic acids encoding neutralizing anti-CCL20 antibodies |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5079228A (en) * | 1990-02-05 | 1992-01-07 | Board Of Regents, The University Of Texas System | Peptide inhibitors of neutrophil activating factor induced chemotaxis |
WO1992004372A1 (en) * | 1990-09-12 | 1992-03-19 | The Scripps Research Institute | Active site of interleukin-8: polypeptide analogs and antibodies |
WO1993011159A1 (en) * | 1991-12-04 | 1993-06-10 | The Biomedical Research Centre Limited | Human interleukin-8 analogs |
US5234911A (en) * | 1990-07-09 | 1993-08-10 | Gist-Brocades, N.V. | Substance with interleukin-8 inhibiting activity and process for its preparation |
-
1995
- 1995-09-22 WO PCT/US1995/012099 patent/WO1996009062A1/en active Application Filing
- 1995-09-22 AU AU36817/95A patent/AU3681795A/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5079228A (en) * | 1990-02-05 | 1992-01-07 | Board Of Regents, The University Of Texas System | Peptide inhibitors of neutrophil activating factor induced chemotaxis |
US5234911A (en) * | 1990-07-09 | 1993-08-10 | Gist-Brocades, N.V. | Substance with interleukin-8 inhibiting activity and process for its preparation |
WO1992004372A1 (en) * | 1990-09-12 | 1992-03-19 | The Scripps Research Institute | Active site of interleukin-8: polypeptide analogs and antibodies |
WO1993011159A1 (en) * | 1991-12-04 | 1993-06-10 | The Biomedical Research Centre Limited | Human interleukin-8 analogs |
Non-Patent Citations (1)
Title |
---|
THE JOURNAL OF BIOLOGICAL CHEMISTRY, Volume 269, Number 23, issued 10 June 1994, CLARK-LEWIS et al., "Structural Requirements for Interleukin-8 Function Identified by Design of Analogs and CXC Chemokine Hybrids", pages 16075-16081. * |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7138498B2 (en) | 1994-08-23 | 2006-11-21 | Human Genome Sciences, Inc. | Antibodies to MCP-4 |
US7183081B2 (en) | 1994-08-23 | 2007-02-27 | Human Genome Sciences, Inc. | Human Ckβ-10 polynucleotides |
US6921645B2 (en) | 1994-08-23 | 2005-07-26 | Human Genome Sciences, Inc. | Antibodies to chemokine β-4 |
US6673344B1 (en) | 1994-08-23 | 2004-01-06 | Human Genome Sciences, Inc. | Antibodies to human CKβ-10/MCP-4 |
US6391589B1 (en) | 1994-08-23 | 2002-05-21 | Human Genome Sciences, Inc. | Human chemokine beta-10 mutant polypeptides |
US6174995B1 (en) | 1994-08-23 | 2001-01-16 | Haodong Li | Human chemokines, CKβ4 and CKβ10/MCP-4 |
US6458349B1 (en) | 1995-06-02 | 2002-10-01 | Human Genome Sciences, Inc. | Chemokine β-4 polypeptides |
WO1997000893A1 (en) * | 1995-06-20 | 1997-01-09 | Chiron Corporation | Interleukin-8 receptor binding compounds |
EP0807439A3 (en) * | 1996-05-14 | 1998-03-11 | Smithkline Beecham Corporation | Method of treating sepsis and adult respiratory distress syndrome |
US6406688B1 (en) | 1996-05-14 | 2002-06-18 | Human Genome Sciences, Inc. | Method of treating sepsis and ARDS with chemokine β-4 |
US6290948B1 (en) * | 1996-05-14 | 2001-09-18 | Smithkline Beecham Corporation | Method of treating sepsis and ARDS using chamohine beta-10 |
AU713675B2 (en) * | 1996-07-05 | 1999-12-09 | Virocell Inc. | Interleukin-8 as an antiviral and antitumor agent |
WO1998001150A1 (en) * | 1996-07-05 | 1998-01-15 | Virocell, Inc. | Interleukin-8 as an antiviral and antitumor agent |
US5900235A (en) * | 1996-07-05 | 1999-05-04 | Virocell Inc. | Interleukin-8 as an antiviral and antitumor agent |
WO2001072830A3 (en) * | 2000-03-31 | 2002-06-20 | Ipf Pharmaceuticals Gmbh | Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using a specific chemokine receptor analysis and the chemokine receptor-ligand interaction |
US7375192B2 (en) | 2002-05-01 | 2008-05-20 | Human Genome Sciences, Inc. | Antibodies that specifically bind to chemokine beta-4 |
US7943741B2 (en) | 2002-05-01 | 2011-05-17 | Human Genome Sciences, Inc. | Antibodies that specifically bind to chemokine β-4 |
JP2007533300A (en) * | 2003-10-22 | 2007-11-22 | アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ | Novel CXCL8 antagonist |
WO2005040210A3 (en) * | 2003-10-22 | 2005-06-23 | Applied Research Systems | Novel cxcl8 antagonists |
WO2006101439A1 (en) * | 2005-03-23 | 2006-09-28 | Astrazeneca Ab | Screen |
US9133273B2 (en) | 2010-11-19 | 2015-09-15 | Eisai R&D Management Co., Ltd. | Nucleic acids encoding neutralizing anti-CCL20 antibodies |
US9809647B2 (en) | 2010-11-19 | 2017-11-07 | Eisai R&D Management Co., Ltd. | Neutralizing anti-CCL20 antibodies |
Also Published As
Publication number | Publication date |
---|---|
AU3681795A (en) | 1996-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1993009799A1 (en) | Suppression of megakaryocytopoiesis by macrophage inflammatory proteins | |
US20110076234A1 (en) | Peptides comprising an isodgr motif | |
US5795859A (en) | Peptide which abrogates TNF and/or LPS toxicity | |
US20070160574A1 (en) | Design of CXC chemokine analogs for the treatment of human diseases | |
US5877276A (en) | Polypeptide agonists for human interleukin-8 | |
US6447766B1 (en) | Method of mobilizing hematopoietic stem cells | |
WO1996009062A1 (en) | Polypeptide agonists and antagonists of human interleukin-8 | |
US5627156A (en) | Polypeptide agonists for human interleukin-8 | |
KR101477767B1 (en) | Antagonists for the interaction between PF4 and RANTES | |
US5912232A (en) | Anti-inflammatory polypeptide antagonists of human I1-8 | |
WO1993009794A1 (en) | Suppression of megakaryocytopoiesis by neutrophil activating peptide-2 | |
US5587457A (en) | Neutrophil stimulating peptides | |
WO2008152508A2 (en) | Cytokine conjugate | |
US6375928B1 (en) | Neutrophil stimulating peptides | |
Rathjen et al. | Differential effects of small tumour necrosis factor-alpha peptides on tumour cell cytotoxicity, neutrophil activation and endothelial cell procoagulant activity | |
US6107273A (en) | Tumor necrosis factor inhibitors | |
WO1993006128A1 (en) | Tnf antagonist peptides | |
EP0519976A1 (en) | Neutrophil stimulating peptides. | |
EP0521918A1 (en) | Anti-tumour peptides | |
AU673332C (en) | Peptide which abrogates TNF and/or LPS toxicity | |
EP1033997B1 (en) | Method of mobilizing hematopoietic stem cells | |
AU676842B2 (en) | Neutrophil stimulating peptides | |
AU684539B2 (en) | Macrophage inflammatory proteins-3, -4 and -1 Gamma | |
AU7467391A (en) | Anti-tumour peptides | |
CA2178927A1 (en) | Peptide inhibitors of cxc intercrine molecules |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |